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vAbstract
Stroke is the third most common cause of death and a leading cause of disability
in the United States. The existing treatments of acute ischemic stroke (AIS) involve
pharmaceutical thrombolytic therapy and/or mechanical thrombectomy. The Food and
Drug Administration (FDA)-approved recombinant tissue plasminogen activator (tPA)
administration for treatment of stroke is efficacious, but has a short treatment time
window and is associated with a risk of symptomatic hemorrhage. Other than tPA, the
Mechanical Embolus Removal in Cerebral Ischemia (MERCI) retriever system and the
Penumbra Aspiration system are both approved by the FDA for retrieval of
thromboemboli in AIS patients. However, the previous clinical studies have shown that
the recanalization rate of the MERCI system and the clinical outcome of the Penumbra
system are not optimal. To identify the variables which could affect the performance of
the thrombectomy devices, much effort has been devoted to evaluate thrombectomy
devices in model systems, both in vivo and in vitro, of vascular occlusion. The goal of
this study is to establish a physiologically realistic, in vitro model system for the
preclinical assessment of mechanical thrombectomy devices.
In this study, the model system of cerebrovascular occlusion was mainly
composed of a human vascular replica, an embolus analogue (EA), and a simulated
physiologic mock circulation system. The human vascular replica represents the
geometry of the internal carotid artery (ICA)/middle cerebral artery (MCA) that is
derived from image data in a population of patients. The features of the vasculature were
vi
characterized in terms of average curvature (AC), diameter, and length, and were used to
determine the representative model. A batch manufacturing was developed to prepare the
silicone replica.
The EA is a much neglected component of model systems currently. To address
this limitation, extensive mechanical characterization of commonly used EAs was
performed. Importantly, the properties of the EAs were compared to specimens extracted
from patients. In the preliminary tests of our model system, we selected a bovine EA with
stiffness similar to the thrombi retrieved from the atherosclerotic plaques. This EA was
used to create an occlusion in the aforesaid replica. The thrombectomy devices tested
included the MERCI L5 Retriever, Penumbra system 054, Enterprise stent, and an
ultrasound waveguide device. The primary efficacy endpoint was the amount of blood
flow restored, and the primary safety endpoint was an analysis of clot fragments
generated and their size distribution.
A physiologically realistic model system of cerebrovascular occlusion was
successfully built and applied for preclinical evaluation of thrombectomy devices. The
recanalization rate of the thrombectomy device was related to the ability of the device to
capture the EA during the removal of the device and the geometry of the
cerebrovasculature. The risk of the embolic shower was influenced by the mechanical
properties of the EA and the design of the thrombectomy device.
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1Chapter I: Introduction
Brief Review: Anatomy of the Circle of Willis and Cerebral Blood Circulation
Cerebral blood flow is provided by two main pairs of arteries: the vertebral
arteries (VAs), and the internal carotid arteries (ICAs). The VAs arise from the
subclavian arteries and unite to form the basilar artery (BA). The posterior cerebral
arteries, which extend from the terminal bifurcation of the BA, connect to the ICA by
posterior communicating arteries at P1/P2 junction, and supply blood to the posterior
circulation of the brain (Figure 1-1).
Figure 1-1 3D reconstruction of human intracranial arteries that form the circle of Willis (ACoA:
anterior communicating artery, ICA: internal carotid artery, PCA: posterior cerebral
artery, BA: basilar artery, PCoA: posterior communicating artery, MCA: middle
cerebral artery, A1: A1 segment of the anterior cerebral artery, A2: A2 segment of the
anterior cerebral artery).
BA
PCA
PCoA
ICA
MCA
A1
ACoA
A2
2About 70% of the common carotid blood flow is diverted into the ICA1-3, and the
ICA bifurcates into the middle cerebral artery (MCA) at the level of the olfactory trigone
and anterior cerebral artery (ACA) opposite the olfactory trigone4. The left and right
ACA are connected by the anterior communicating artery to form the anterior circulation.
The arterial polygon which provides communication between the anterior and posterior
circuits, shown in Figure 1-1, is known as the circle of Willis (CoW)4-7. The CoW
represents a multiplexer and is regarded as the principal source of collateral flow in
patients with ischemic cerebrovascular disease8. The ability of the CoW to redistribute
blood flow is affected by the presence and diameter of the component vessels. Three-
dimensional time-of-flight was used to determine the morphologic differences of the
CoW among 150 healthy subjects, and the results show that only 42% of the subjects
presented a complete CoW9. The most common variants include absence of the anterior
communicating artery and one of the posterior communicating arteries. Typical variations
are presented in Figure 1-2. Apart from the CoW, small pial vessels may also provide
collateral flow in an acute ischemic event. A recent clinical study shows that stroke
patients with higher pial collateral scores have improved clinical outcomes and smaller
infarct volume as compared to those with lower pial collateral scores following intra-
arterial tissue plasminogen activator (IA-tPA) treatment10.
The brain requires continuous and sufficient blood perfusion that is approximately
15% of the cardiac output. The anterior circulation contributes 76-82% to the global
cerebral blood flow11, 12. The capability of brain to store energy is low, as demonstrated
by the finding that the adenosine triphosphate level quickly drops to zero in 7 minutes
3after the termination of the oxygen supply13. The shortage of the oxygen stops cell
growth; in addition, the deprivation of blood flow to the brain renders neurons unable to
maintain the physiological ion gradient14 that they need to function properly, and causes
neuronal dysfunction and subsequent death. In a typical acute ischemic stroke that is
caused by a large artery occlusion, 1.9 million neurons, 14 billion synapses and 7.5 miles
of myelinated fibers are lost each minute15 . Acute ischemic stroke is a major cause of
neurological deficiencies.
Figure 1-2 Common variations of the CoW16.
4Acute ischemic Stroke
Significance and Impact of AIS
Stroke is the second highest cause of mortality in the world17 . In the United
States, cardiovascular disease, principally heart disease and stroke, is the leading cause of
death18. The 2010 Heart Disease and Stroke Statistical Update from American Heart
Association19 reports that about 795,000 people experience a new or recurrent stroke each
year, and stroke accounted for about 1of every 18 deaths in the United States in 2006. On
average, a stroke occurs every 40 seconds, and someone dies of a stroke every 4 minutes.
The financial burden of stroke is high, with the estimated direct and indirect cost at 73.7
billion in 2010 (in US dollars).
According to the World Health Organization20, stroke is defined as, “rapidly
developing clinical signs of focal (at times global) disturbance of cerebral function,
lasting more than 24 hours or leading to death with no apparent cause other than that of
vascular origin.” Some modifiable risk factors for stroke include diabetes, hypertension,
elevated cholesterol, and smoking21. Nonmodifiable factors are age, race, gender and
family history.
Cerebral blood flow (CBF) is determined by the ratio of cerebral perfusion
pressure (CPP) and cerebrovascular resistance22, and the CPP is generally described as
the difference between mean arterial blood pressure and intracranial pressure13. The
regional CBF of the normal brain tissue is about 50-60 ml/100g/min23. When the cerebral
ischemia occurs, the cessation of blood flow results in varying gradients in hypoperfusion
5over the affected region24.  The central zone (CBF<12 ml/100g/min25) is termed
“ischemic core” which is composed of the irreversibly and severely damaged tissue26,
and is surrounded by presumably viable tissue, namely the ischemic penumbra. The
penumbra is a zone of tissue that receives insufficient blood flow (CBF:18-20
ml/100g/min25) to function properly and is at risk of irreversible damage should blood
flow not be restored.  The salvage of ischemic penumbra may be achieved when the
reperfusion is established within 6 to 8 hours27, and the penumbra is the target area to
preserve for prevention of further neuronal deterioration. It is important to note that the
evolution of the infarct and penumbral zone is dynamic and controlled by a number of
factors including spontaneous fibrinolysis and systemic blood pressure. The oligemic
tissue in the area between the unaffected brain and the ischemic penumbra is mildly
hypoperfused and presents no functional or morphological impairment23.
Frequent Locations of AIS and Clinical Symptoms
Of all strokes, 87% are ischemic and 13% are of hemorrhagic origin19. Five
subtypes of the ischemic stroke are denoted according to data from the National Institute
of Neurological Disorders and Stroke (NINDS) Stroke Data Bank. They are: 1. large-
artery stenosis occlusion/atherosclerosis (8.9%), 2. embolism from a commonly accepted
cardiac source (19.3%), 3. small-artery occlusion (lacune, 26.5%), 4. infarct with
undetermined cause (39.9%), and 5. infarction with associated extracranial arterial
pathology including embolism from a carotid source (5.4%)28-30.
6The origin of AIS can be attributed to local thrombosis, embolism from an
upstream source or hemodynamics (hypoperfusion)31, 32, with in situ thrombosis being the
most common33. Thrombosis is a cascade of platelet-mediated events that result in blood
coagulation with the presence of the dynamic shear stress, clotting factors, and other
proteins and cells, whereas clotting generally refers to the polymerization of fibrinogen to
fibrin in regions of stagnant blood flow34. Ischemia due to thrombosis is normally led by
the excessive thrombus developed over the atherosclerotic plaque or an abnormality of
blood clotting31. More frequently, thrombus forms at other locations, e.g. the common
carotid artery bifurcation, and the thrombus may eventually break away from the plaque
to form a cerebrovascular “embolus”-- meaning “plug” in Greek. The embolus is swept
downstream by the circulating blood and lodges within a cerebral vessel, often at
bifurcation sites, resulting in an artery-to-artery embolism. Aside from atherosclerotic
plaques, other common sources of cerebral emboli are of cardiac origin associated with
such diseases as atrial fibrillation (AF), infective endocarditis, mitral stenosis, myocardial
infarction, patent foramen ovale and prosthetic mechanical valves35-38. Although it is
difficult to estimate the origin of the embolus in stroke patients, cardioembolic stroke
accounts for approximately 20% of all ischemic strokes, and about 15-20% of ischemic
strokes occur in patients with AF36, 39, 40. Hemodynamically determined infarction
happens when the proximal blood supply to the brain is unavailable (e.g., cardiac arrest,
arterial dissection), and collateral compensatory blood flow is insufficient either due to
global hypoperfusion31 or normal anatomical variants.
7Stroke related disability varies depending on the location and extent of the
affected area. The most common site for large vessel occlusion is the MCA (Figure 1-
3)41-44. Clinical symptoms such as acute hemiparesis, hemisensory loss, hemianopia,
visuospatial neglect, and aphasia are attributed to infarction of the MCA territory45, 46.
Due to the fact that the MCA is the most common site of AIS, a model system mimicking
human MCA occlusion is developed in this study for thrombectomy device testing.
Figure 1-3 Angiogram of a typical stroke patient where the middle cerebral artery is occluded
(arrow).
AF and AIS
Embolic stroke due to AF is a common observation; and patients with AF account
for half of all patients with cardioembolic stroke47, 48. In AF, the disorganized electrical
signals in the atria cause independent depolarization of atrial muscle fibers, and the atria
quiver instead of beating effectively. The blood is not completely pumped out from the
8atrium to the ventricleresulting in a consequent tendency of thrombogenesis (the
pathogenesis of thrombus formation). The mechanism of thrombogenesis in AF may be
understood according to the Virchow triad49, in which three components including
abnormal changes of blood flow, blood constituents, and vessel wall are proposed 50.
Figure 1-4 Structural features of the blood vessels51.
The lining of the atrium, as with the entire circulatory system, is made of
endothelial cells (ECs), which are directly exposed to the blood flow and supported by
the internal elastic lamina (Figure 1-4). It has been noted that ECs do not act as a passive
barrier; on the contrary, via shear stress from the circulating blood flow they adjust
vascular tone by producing nitric oxide and play an important role in blood coagulation,
fibrinolysis, angiogenesis (formation of new blood vessel), inflammation by expressing
thrombomodulin, synthesizing von Willebrand factor (vWf), and releasing substances
9such as tissue-type plasminogen activator, P-selectin and tissue factors52, 53 54, 55. In AF,
blood stasis in the atrium, especially in the left atrial appendage (Figure 1-5), decreases
the antithrombotic activity of ECs, and allows thrombin and fibrinogen to settle at the
vessel wall, thereby facilitating thrombus formation54.
Turnover of extracellular matrix (ECM), endothelial dysfunction and denudation
occur as a consequence of AF (Figure 1-5). The abnormal changes in ECM induce
fibrosis and infiltration of the endocardium, and further promote thrombogenesis.
Damage of the ECs give rise to an elevated vWf level, which promotes platelet adhesion
and activation of blood coagulation56.
Figure 1-5 Thrombogenesis in atrial fibrillation: Virchow’s triad revisited50.
10
A hypercoagulable state in AF induced by abnormal changes in blood constituents
such as fibrin D-dimer and platelets has been well-investigated57-59.  It is found that
patients with AF have increased amount of plasma D-dimer, a marker of the activation of
the coagulation system60, and β-thromboglobulin, a platelet-specific protein which is
released during platelet aggregation and thrombus formation50. If the thrombus formed in
the atrium is dislodged from the heart, an embolus can travel to an artery that supplies
blood to the brain producing a cardioembolic stroke.
Atherosclerosis and AIS
The Northern Manhattan Stroke Study conducted between 1993 to1997 reveals
that the prevalence of the intracranial atherosclerotic disease (ICAD)-related ischemic
strokes is 3, 15, and 13 per 100,000 people for white, African American, and Hispanic
subjects, respectively61. ICAD-related strokes account for 9, 17, and 15% of all ischemic
strokes among white, African American, and Hispanic patients, respectively62. A higher
incident rate of ICAD-related stroke (33 to 37% of all ischemic strokes) is observed in
the Chinese population63. As mentioned earlier, expansion of the plaque and disruption of
the unstable atherosclerotic plaque are two risk factors responsible for the occurrence of
the AIS64. The plaque is morphologically characterized by a thin fibrous cap, a large
atheromatous core, lipid-laden macrophages and reduced number of smooth muscle cells
(Figure 1-6). There are two mechanisms by which intracranial plaques cause AIS, 1.
Acute plaque rupture with distal embolus or 2. In situ thrombosis leading to occlusion of
the vessel at the site of the plaque with or without plaque rupture.
11
Atherosclerosis is the thickening and hardening of the arteries due to the build-up
of the fatty substances (“athero” means fatty, and “sclerosis” means scar). Risk factors
for atherosclerosis include aging, diet, hypertension, smoking, and family history. The
deposition, aggregation and oxidation of the low density lipoproteins (LDLs) are thought
to trigger the progression of the atherosclerotic lesion65, 66. Oxidized LDL injures the
endothelium and causes the endothelial cells to express endothelial leukocyte adhesion
molecule-167, which attracts certain kinds of white blood cells such as monocytes and T-
lymphocytes to the vessel wall57. With time, the monocytes transmigrate across the
endothelial cells to form the foam cells (macrophages filled with cholesterol esters), and
stimulate the growth of the smooth muscle cells (SMCs) from the media (Figure 1-6)51, 68.
The development of the plaque can be classified into two different types: diffuse dilative
atherosclerosis and focal stenotic atherosclerosis69.
Figure 1-6 Various components of the atherosclerotic lesion of the human carotid endarterectomy
specimen were identified by a color-coded image70.
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The diffuse dilative atherosclerosis is seen when smooth muscle cells and
collagen fibers are accumulated in a slow and continuous manner. The presence of a large
numbers of smooth muscle cells and collagen fibers increases the thickness of the fibrous
cap, and strengthens the plaque structure, resulting in a stable fibroatheroma. A
compensatory local dilation of the artery (vascular remodeling) is usually observed and
assumed to be the final stage of this type of disease progression71, 72.
The focal stenotic atherosclerosis is a rapid and unpredictable process.
Compositional changes of the plaque could happen as a result of a multi-factorial process
and make the plaque vulnerable. Vascular smooth muscle cells (VSMCs) synthesize
collagen type I and III, and the balance between the collagen synthesis and degradation
determines the stability of the fibrous cap73, 74. Previous studies have found that the
cytokine interferon gamma, a product of activated T-cells, inhibit the collagen synthesis
and induce VSMCs apoptosis75, 76. The inflammatory cells are found to be infiltrated and
cluster in the shoulder region of the plaque, where disruption usually takes place. In
addition, the foam cells die by necrosis or apoptosis, resulting in extracellular lipid
deposition77, and reduce the strength of the fibrous cap located between the lipid-rich
atheromatous core and the endothelial layer 78-80. The abovementioned determinants all
make the plaque prone to rupture, and lead to excessive thrombus formation (thrombosis)
over the ruptured plaque (Figure 1-7) 69, 81, 82.
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Figure 1-7 (Left) Thrombus is formed over a disrupted atherosclerotic plaque. 61 The close-up view
of the lipid core, where cholesterol crystals are seen82.
When the vessel wall is injured or the fibrous cap of the atherosclerotic plaque is
ruptured, vWf binds to the exposed connective tissue, followed by the adhesion of
platelet through the membrane-bound receptor glycoprotein Ib83. The injured
endothelium exposes tissue factor (TF) to factor VII (FVII), and the resulting product,
activated factor VII /TF complex is then able to enzymatically catalyze factor X,
initiating the extrinsic coagulation pathway shown in Figure 1-8 84-86. Activated factor X
combines with factor Va to form prothrombinase and further support thrombin generation.
Thrombin, coupled with adenosine diphosphate and thromboxane A2 secreted by
activated platelets, contribute to platelet aggregation and produce a stable fibrin
thrombus87.
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Figure 1-8 Mechanisms of clotting factor interactions88.
FDA-Approved Pharmacological Treatment of AIS
Intravenous fibrinolytic therapy with tissue plasminogen activator (IV-tPA) is the only
approved pharmacological treatment for acute ischemic stroke89. The product of the tPA-
mediated plasminogen activation, plasmin, cleaves and degrades fibrin90, 91. The NINDS
rt-PA Stroke trial, a randomized, double-blinded clinical trial, proved that a reperfusion
strategy with IV-tPA dramatically improves patient outcome92. Figure 1-9 demonstrates
that a greater proportion of patients left with minimal or no deficit 3 months after tPA
therapy as indicated by mRS 3 or less. As compared with the placebo treatment, tPA
therapy was not accompanied by an increase in severe disability and mortality. Mortality
at three months was 17% in the t-PA group and 21% in the placebo group.
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Figure 1-9 Clinical outcomes at 90 days by modified ranking scale (mRS) in the NINDS rt-PA Stroke
Trial. The outcome measure favors the t-PA group92.
However, this approach has severe limitations including short time window
(within 3 hours of onset)43, risk of symptomatic hemorrhage, and numerous
contraindications93. Ultimately, this results in a low percentage of patients, 1-3%94,
eligible to receive this therapy. Note, the modified Rankin Scale (mRS) indicates the
level of neurological disability on a 0-6 scale, where 0 is no neurological impairment and
6 is death. Importantly, a mRS score less than or equal to 2 signifies that the patient is
capable of independent living and this is a commonly used threshold for therapeutic
efficacy studies.
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FDA-Approved Mechanical Thrombectomy Devices for AIS
There are two FDA-approved endovascular devices for the treatment for acute
ischemic stroke, namely, the MERCI retriever system and the Penumbra System94-96. The
MERCI retriever system (Concentric Medical Inc, Mountain View CA) is a flexible
tapered nitinol wire with several helical loops that is deployed via a microcatheter and
embedded within the thrombus for retrieval. An improvement in neurological outcome
with the use of the X6 Merci Retriever (Figure 1-10 (a)) 8 hours after onset of ischemic
symptoms (beyond the traditional 6-hour window) was reported97. The final results of the
multi-MERCI trial published in 2008 shows an improvement in the recanalization rate by
using new generation L5 MERCI (Figure 1-10 (b)) to treat patients with large vessel
occlusion98.
Figure 1-10 (a) The Merci non-filamented (X6) and (b) filamented retriever (L5)
(Image source: Concentric Medical Inc, Mountain View CA)
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The recanalization rates of the old (X5/X6) and new (L5) MERCI devices without
adjunctive therapies are 46% and 57%, respectively. With adjunctive IA therapies (other
mechanical interventions or administration of tPA or glycoprotein IIB/IIIA inhibitors),
the recanalization rates of old (X5/X6) and new (L5) MERCI device are 64% and 70%,
respectively. The mortality at 90 days is 34%, and symptomatic intracranial hemorrhages
occurred in 10% of the patients. A final recanalization rate of 68% is reported, and
overall, 36% of patients have a mRS score ≤ 2 after 90 days. Importantly, almost half of
the patients (49%) in which recanalization is achieved have an independent lifestyle
(mRS ≤ 2) after 90 days, as compared to only 9.6% in those patients in whom the
intervention failed (Figure 1-11). More than half of the patients in whom
revascularization was not achieved die within 90 days after the MERCI treatment. These
data, which show an increase in independent living and a reduction in mortality when
mechanical revascularization is achieved, have been consistent across all of the MERCI
trials and provide a strong impetus for device mediated vessel recanalization.
Figure 1-11 Clinical outcomes at 90 days by mRS show an increase in independent living and a
reduction in mortality when mechanical revascularization is achieved98.
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Comparisons between the recanalization rate, functional status and mortality
reported in the multi-MERCI trial and the PROACT II study are available99. In the
PROACT II study, intra-arterial prourokinase recanalized 66% of the MCA occlusions,
whereas the MERCI retriever restored the blood flow in 68% of the patients with the
large vessel occlusions in the MCA, the carotid terminus or vertebrobasilar arteries. In
the PROACT II study, an overall mortality is 25%, and 40% of the patients show
favorable outcome (mRS≤ 2) at 3 month follow-up. Despite similar recanalization rates,
the mortality presented in the multi-MERCI trials is higher than that reported in the
PROACT II study, which could be due to the difference in the inclusion criteria as
described above. Recently, Merci and Multi Merci investigators parsed their data for
patients who would have been eligible for enrollment in PROACT II99. They were able to
conclude that mortality was indeed explained by baseline stroke characteristics and trial
design, and did not differ between the relevant patients in the MERCI trials and
PROACT II control arm. Moreover, embolectomy produced similar functional outcome
results in this subset of MERCI/multi-MERCI patients as compared to the PROACT II
treatment arm. It is important to mention that adjusted comparisons were hampered by
the failure to obtain access to the individual patient level data from PROACT II.
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The second, more recently FDA-approved thrombectomy device is the Penumbra
Aspiration System (Figure 1-12) consists of a reperfusion catheter, a separator, and a
vacuum pump that removes the thrombus through 2 mechanisms: maceration and
aspiration.
Figure 1-12 Reperfusion Catheter/Separator pairs are available in numerous sizes (left). The
Penumbra reperfusion suction pump is connected to the Penumbra reperfusion catheter
by an aspiration tubing and provides continuous suction when activated (right) (Courtesy
of Penumbra, Inc., Alameda, CA)
In a recent clinical trial100, the safety and effectiveness of the Penumbra system
were tested in the treatment of 125 acute stroke patients. Before treatment, the average
mRS of 125 patients was 4.5±0.8, and 96% had Thrombolysis in Myocardial Infarction
(TIMI) 0 flow (no perfusion). The target vessel locations included ICA (18%), MCA
(70%), vertebrobasilar (9%) and others (3%). The clinical outcome showed the Penumbra
system was effective in revascularization, and resulted in 82% achievement of TIMI 2
(partial perfusion of the artery with incomplete or slow distal branch filling) or TIMI 3
(complete perfusion of the artery) flow. At 30-day follow-up, 42% of patients had a good
clinical outcome, which was defined as a ≥ 4 points improvement in National Institutes of
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Health Stroke Scale (NIHSS) score or mRS score ≤ 2. The mortality rate was 26% and
the rate of symptomatic hemorrhage was 11%. Interestingly, in those patients in which
the primary lesion was recanalized, only 29% had an mRS ≤ 2 after 90 days. That is
nearly half the number of patients with an independent lifestyle than observed in the
multi-MERCI trial following successful recanalization. It is reasonable to hypothesize
that mitochondrial dysfunction triggered by the initial injury, inflammatory processes,
initiation of apoptosis, and the distal emboli from maceration of the occlusive embolus
may be potential explanation for this observation. Safety parameters, such as device
related serious adverse events and rate of intracerebral hemorrhage were found to be
comparable with historical controls.
Other Treatments for AIS
There are a variety of minimally-invasive treatments for acute ischemic events
such as endovascular snares101, balloon angioplasty42, 102, intracranial stenting103, and
selective intra-arterial infusion of thrombolytic agents. During balloon angioplasty, the
revascularization is achieved by inflating the balloon at the occlusion site to flatten or
compress the plaque or thrombus. Improved clinical outcome after balloon angioplasty in
patients who are resistant to intra-arterial thrombolysis has been documented104; however,
the drawbacks of the balloon dilation such as risks of elastic recoil and dissection limit
the applicability of this technique105. Favorable clinical outcomes (79% recanalization
rate) with another endovascular treatment, balloon expandable stent, are also observed in
previous studies106, 107. Balloon-assisted stenting provides higher radial force as compared
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to balloon angioplasty, but the overexpansion of the stent may cause vessel damage105. In
addition, the rigidity of the stent influences the deliverability in the tortuous intracranial
circulation during the treatments of the intracranial diseases.
The recently available self-expanding stent combines the advantages of balloon
angioplasty and balloon-assisted stenting, and is more suitable for the treatment of acute
cerebrovascular occlusions108.  The self-expanding stent is more flexible and applies less
radial outward force against the vessel wall. In a first FDA-approved prospective trial of
primary intracranial stenting for acute stroke109, the safety of the Wingspan intracranial
self-expanding stent system (Boston Scientific) was evaluated in 20 enrolled patients
with AIS. A 100% recanalization rate was reported (12 patients had TIMI 3 and 8
patients had TIMI 2), and at 1-month follow-up, mRS ≤3 was achieved in 12 patients and
mRS ≤1 was achieved in 9 patients. The promising results from this trial suggest the
potential utility of the self-expanding stent in the treatment of AIS. The one drawback of
the technique is the permanent implantation of a metallic endoprosthesis, which
necessitates proper anti-platelet therapy. The administration of antiplatelet medications
could complicate the risk of increased frequency or severity of intracranial bleeding. The
concept of using the stent as a retriever was also documented in the previous studies.
Wakhloo and Gounis first demonstrated the use of self-expanding stents for clot removal
in the laboratory110. This technique has been applied clinically where the Solitaire FR
(flow restoration) Revascularization Device (ev3, Irvine, California) successfully
recanalized 90% of cases where the MERCI retriever had previously failed111.
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Ultrasound refers to sound waves with frequencies above 20 kHz, and is
generated by a piezoelectric transducer. The transducer receives the electric input and
vibrates when the frequency of the voltage reaches the resonance frequency of the
piezoelectric material. The vibration is then transmitted as ultrasonic pressure waves.
Two commonly used frequency ranges in medicine are assigned as low (20-400 kHz) and
high (0.5-3 MHz) frequency112. Low frequency, high power ultrasound has better tissue
penetration, and is utilized therapeutically. Currently, there are three different approaches
to execute ultrasound thrombolysis: transcranial ultrasound thrombolysis113, catheter-
delivered transducer tipped ultrasound thrombolysis114, and catheter-delivered external
transducer ultrasound thrombolysis115, 116. One of the main mechanisms by which
ultrasound thrombolysis occurs is called “cavitation”. Cavitation happens when a fluid is
violently agitated, and it involves creation, growth, oscillation, and collapse of bubbles in
the medium. During negative phase of the ultrasound wave, the microbubbles form in the
thrombus. These bubbles collapse and give rise to a series shock waves causing thrombus
fragmentation112. Other forces produced from the bubble dynamics such as shear stress
and liquid jets also contribute to the clot ablation117.
Hong et al. employed a flexible titanium wire probe to disrupt the whole blood
clot and cell-free fibrin clot in test tubes118. A continuous ultrasound wave was generated
and delivered by an ultrasonic lithotripsy generator at a frequency of 20 kHz. It was
observed that a 56 cm wire probe broke a 1.2 g whole blood clot in 45 seconds, and clot
age had no effect on the time required for disruption. Debris as large as 80 μm was
detected in the disrupted whole blood clot solution, while the size of the disrupted cell-
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free fibrin clots was around 40 μm. Halkin et al. illustrated the ultrasound thrombolytic
effect on cardiac vessel patency112. In coronary arteries, ultrasound wave decreased the
degree of stenosis and increased the coronary blood flow. The safety and efficacy of the
coronary ultrasound thrombolysis by using catheter-delivered external transducer
ultrasound system were also documented in the previous animal data and clinical results.
In this thesis work, the application of waveguide ultrasound technique is expanded to the
ablation of the clot in cerebral arteries where the vessel geometry is more complex and
tortuous. The waveguides are different than the EKOS ultrasound device (EKOS
Corporation, Bothell, Washington, USA). The EKOS ultrasound device is delivery
concurrently with infusion of a thrombolytic agent through the microcatheter. The
acoustic pressure gradient generated by the ultrasound moves the drug into the clot and
accelerates its dissolution. On the other hand, the waveguide ultrasound technique
disrupts the clot by cavitation with a waveguide due to its mechanical motion (vibration)
induced by the ultrasound energy. The success of this design may provide another option
for physicians to treat patients with acute ischemic stroke.
Specific Aims
There is an incomplete understanding of the anatomy and physiology leading to
stroke. Therefore, I hypothesize that AN ANATOMICALLY AND
PHYSIOLOGICALLY REPRESENTATIVE MODEL SYSTEM OF
CEREBROVASCULAR OCCLUSION IS REQUIRED AND CAN BE BUILT FOR
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EVALUATION OF MECHANICAL THROMBECTOMY DEVICES IN-VITRO. To
test this hypothesis, I propose the following specific aims:
Specific Aim I: To create a representative in-vitro model of human focal, vascular
occlusion
a. To build realistic models of human intracranial vasculature and a flow loop to
simulate human cerebral circulation. Brain magnetic resonance angiography (MRA) data
sets from normal patients are collected for the geometric analysis, and the results from
the vessel characterization are used to determine the best matching vasculature to build
replicas with representative anatomical features by using a novel batch manufacturing
process. A transparent replica with uniform wall thickness is connected to a flow loop
which consists of a computer-controlled cardiac pulse duplicator, flow probes, pressure
transducers, and data acquisition system to simulate and monitor human intracranial
hemodynamics for testing of the thrombectomy devices.
b. To prepare and characterize EAs. EAs will be created to occlude the silicone
replica mimicking the acute arterial occlusion in human. Impacts of species, thrombin
and barium sulfate concentration on the mechanical properties of the EAs will be
investigated. Moreover, the structural and mechanical characteristics of the EAs will be
compared with those of the human sources of emboli.
Specific Aim II: To evaluate the efficacy of the mechanical thrombectomy device in the
abovementioned model
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The MERCI retrieval system, the Penumbra aspiration system, a self-expanding
stent, and an ultrasonic endovascular system comprising an ultrasonic energy source,
transducer and ultra thin wire are activated to mechanically interact with the embolus
analogues in the flow loop. The flow restoration and particulate size analysis are critical
indicators to determine the efficacy and safety of each device.
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Chapter II: Neurovascular Modeling: Small-Batch Manufacturing of Silicone
Vascular Replicas
Abstract
The objective of this work is to develop an efficient methodology for
manufacturing realistic cerebrovascular replicas. Brain MRA data from 20 patients were
acquired. The centerline of the vasculature was calculated and geometric parameters
measured to quantitatively describe the ICA siphon. A representative model was created
based on the quantitative measurements. Using this virtual model, a mold with core-shell
structure was designed and converted into a physical object by fused deposit
manufacturing. Vascular replicas were created by injection molding of different silicones.
Mechanical properties, including the stiffness and luminal coefficient of friction, were
measured.
The AC, length and curvature of the ICA siphon were 4.15±0.09 mm, 22.60±
0.79 mm and 0.34±0.02 mm-1 (average ± standard error of the mean), respectively. From
these image datasets, a median virtual model was created and this virtual model was
transformed into a physical replica by an efficient batch manufacturing process. The
coefficient of friction of the luminal surface of the replica was reduced by up to 55%
using liquid silicone rubber coatings. Depending on the material used to make the replica,
the modulus ranged from 0.67 to 1.15 MPa compared to 0.42 MPa for a cerebral artery
from human autopsy studies. A population-representative, smooth, and true-to-scale
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silicone arterial replicas with uniform thickness were successfully built for in-vitro
neurointerventional device testing using a batch manufacturing process.
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Introduction
Recent advances in minimally invasive neuroendovascular interventions such as
aneurysm coiling, clot retrieval, balloon angioplasty and stenting have been applied in the
treatment of cerebrovascular diseases103, 119, 120. For the successful development of new
devices designed for the intracranial circulation, in vitro evaluation in realistic vascular
replicas is an important part of the design phase121-124. Of particular importance is the
ICA siphon, which offers challenging tortuosity for endovascular access. Several
different manufacturing processes for fabrication of vascular replicas have been described
previously. Physical 3D vasculature models have been obtained either by injecting
methylmethacrylate into human cadavers to get vascular lumen casts125-132 or by rapid
prototyping based on imaging data129, 130, 132. Different methods, including repeated
painting125, 131, dip-spin processing126, and lost-wax technique128 have been applied to the
casts to form the elastomeric replicas. The procedures mentioned above successfully
fabricated a variety of vascular replicas; however, some limitations of these
manufacturing processes cannot be ignored. First, the high friction resistance on the
surface of silicone impeded the deliverability and deployment of endovascular devices in
the silicone replicas133. Secondly, achieving desired wall thickness by repeated painting
or dip-spin steps was time-consuming and not precise. Importantly, each model was
essentially made by hand, and therefore with limited reproducibility and large time
expenditure.
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The goal of the earlier studies was to make patient-specific silicone models
instead of a model capable of representing the geometry of a population of patients. To
prepare the latter model, vessel characterization is essential. The morphology of
intracranial arteries varies not only from location to location, and patient to patient but
also as a result of a number of diseases134, 135. Therefore, vessel characterization provides
the necessary data upon which to base a population averaged vascular replica. Various
methods are available for vessel characterization in 2D or 3D space136-138, and among
them, tortuosity evaluation is widely discussed. To date, tortuosity lacks a universal
definition137, but is generally used to summarize curvature information along the
centerline of a blood vessel139. Curvature at a point of the space centerline represents the
rate of change of the tangent with respect to the arc length and can be calculated by using
standard formulae from the Frenet-Serret theory of differential geometry140, 141. By
collecting a set of curvature data, the total and average curvature of a vessel segment can
be obtained.
During neuroendovascular therapy, access of neurovascular devices to the anterior
intracranial circulation requires navigation through a relatively tortuous ICA siphon,
where the anatomy can make access difficult142.  In this study, the median AC, length,
and diameter of the ICA siphon from 20 patients were used to build a true-to-scale, batch-
manufactured, transparent silicone replica of a population representative model.
Furthermore, the inner wall of silicone replica was modified by the LSR topcoat to
provide lubricity for the delivery of endovascular devices.
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Materials and Methods
Patient Selection and MR Imaging
Twenty anonymized brain magnetic resonance angiography (MRA) data sets were
acquired from a retrospective review between December 30, 2007 and January 23, 2008
of patients (10 men and 10 women with a mean age 60.4 and 42.1 years old, respectively)
having no pathological findings.  MR imaging was performed using a 1.5T system (GE
Signa Excite, Waukesha, WI) and a receiving 8-channel head coil. Brain 3D time of
flight MRA (TOF MRA) data were acquired (TR, 33.3 ms; TE 6.9 ms; FA, 20º; FOV,
200 x 200mm; matrix 512 x 512; section thickness, 1.4mm with 0.7mm gap).
Vessel Segmentation and Centerline Generation
MRA images were imported slice-by-slice into Mimics (Materialise, Leuven,
Belgium) and stacked to formulate a 3D model (Figure 2-1). The target vasculature was
extracted from the neighboring tissue by thresholding. To generate a segmentation mask,
minimum and maximum threshold values were set and segmentation was further
restricted by cropping the mask. The selected pixels (highlighted in yellow in Figure 2-1)
in each slice were connected, resulting in a clean mask for the use of 3D model
construction. The 3D segmentation object was fixed to assure that there were no shells,
holes, noise or bad edges, and smoothed before skeletonizing. The resulting centerline
was composed of control points equally spaced at a constant 0.4 mm interval.
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Figure 2-1 Mimics displayed the image data in several ways: (upper left) the coronal view, (upper
right) the axial view, (bottom left) the sagittal view, and (bottom right) the 3D view.
Vessel Characterization and Model Selection
The path length of extracted centerline and the diameter of the best fit circle to the
vessel cross-section at each control point were recorded and averaged. The results were
presented as average ± standard deviation.
The AC of left and right ICA siphons of 20 patients was calculated. The vessel
centerline r(s) = [x(s), y(s), z(s)] was first parameterized by arc length, and then fitted
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with a 10th-order polynomial for smoothing. To evaluate the goodness of fit, the degree of
polynomial varying from 2 to 22 was applied to the original data set, respectively, and the
root mean square error (RMSE) was calculated143.
The smoothed centerline was re-sampled to give control points at constant 0.05
mm intervals for curvature evaluation. The curvature (k) at each control point and the AC
were given by140, 141:
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where r’(s) and r”(s) denoted the first and second derivatives of the centerline, and
n indicated the total number of points.
The nonparametric Wilcoxon signed rank test was performed (GraphPad Prism 5,
La Jolla CA) to compare the median of each vessel feature against a hypothetical median,
which was every single geometric parameter for the left and right ICA siphons in each
patient . In this test, p value greater than 0.05 concluded that there was no statistically
significant difference between the median of a group of samples and the hypothesized
median.
Generation of the Vascular Replica
A mold with a core-shell structure was created for silicone injection (Magics,
Materialise, Leuven, Belgium). The inner core, representing the geometry of the
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vasculature was encapsulated by the outer shell which was created based on the geometry
of the core. The distance between the core and shell was the thickness of the silicone
replica, which can be precisely controlled. In this study, the wall thickness was 1 mm.
The virtual design was transformed into a physical object (Prodigy Plus, Stratasys,
Eden Prairie MN) using fused deposit manufacturing to build the model in a layer-by-
layer manner, with a layer thickness of 0.178 mm (Figure 2-2). The extrusion head in the
build envelop was heated to melt both the mold and support materials and was moved in
both horizontal and vertical directions by a numerically controlled mechanism. The
production capacity per batch was determined by the size of the target vasculature. For
instance, 6 ICA-MCA core-shell models with a dimension of 47×41×81 mm3 each can
be built in one batch, and completed in 30 hours.  The dual build heads in the heated
build envelop extruded the model (co-polymer of acrylonitrile, butadiene, and styrene)
and support materials along the designated tool path. Both materials fused together to
form a solid model. The soluble support material was removed in the sodium hydroxide
solution at 70 ºC, which required approximately 24 hours.
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Figure 2-2 Cross-sectional view of the vascular model during the build process
Xylene and 2-propanol were infused into the mold alternately to smooth the core
and the inner wall of the shell. It was found that repeating the alternate rinse procedure
for 5 times, each time for 1 minute, achieved an adequate smoothing result. The rinsed
mold was dried in the ventilation system before silicone infusion.
Sylgard 184 silicone kit (Dow Corning, Midland MI) and an injection molding
grade silicone, LIM 6030 pail kit (Momentive, New Milford CT), were infused into the
core-shell mold. Sylgard 184 replica was found to be optically clear, and had higher
Shore A hardness. Compared to Sylgard 184, LIM 6030 had higher elongation at break,
tensile strength, and viscosity. The amount of thinner SF 96-5 (GES Waterford Plant,
Waterford, NY) added to the LIM 6030 mixture accounted for 7% of total mixture weight.
The silicone solution was mixed and degassed at room temperature under 76 cmHg
vacuum. Higher injection pressure, at least 1200 mmHg, was required for the delivery of
the viscous LIM 6030 as compared to 55 mmHg to infuse the Sylgard 184 into the mold.
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The silicones were cured at 60 oC for 12 hours. The whole mold was immersed in xylene
for mold dissolution overnight.
LSR Topcoat Modification
LSR topcoat (Momentive Performance Materials, Albany NY), a two-component
translucent matte coating with a Brookfield viscosity of 1600 centipoise, was infused into
smoothed, open-ended, straight silicone tubes (11 cm in length, and 4 mm in diameter)
using a peristaltic pump, and then cured at 110oC in a ventilated oven for 30 min. This
procedure was repeated from 0 to 3 times. The effect of multiple coatings on the COF
was evaluated by using a customized friction rig (TA-265A, Texture Technologies Corp,
Hamilton, MA) which was designed according to ASTM D1894. The schematic
illustration of the friction rig was shown in Figure 2-3 (a), and a cone-ring structure was
design to mount the silicone material (Figure 2-3 (b and c)).
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Figure 2-3 (a) The schematic illustration of the friction rig (b) The ring and cone were used to hold
silicone tube material. The tube material was placed against the cone and the slid over it
until a snug fit was achieved (c) A vessel sample (blue arrow) was mounted.
During the friction test, the inner lumen of the replica slid 20 mm over a flat
surface at a sliding speed of 5 mm/sec for 25 times. A 200g weight was placed on the far
end of D to create a higher normal force between the target surfaces. All tribological tests
were conducted under ambient condition with a constant temperature of 21 oC.  Five
specimens were tested for each silicone material, and the average force was obtained to
determine the static and dynamic COF of silicone material before and after LSR coating.
The static COF was obtained from the averaged maximum force initiating motion
between test material and surface, whereas, the dynamic COF was from the average force
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measured for the duration of sliding. The free body diagram of the friction rig system was
presented in Figure 2-4.
Figure 2-4 The friction rig system and its corresponding free body diagram.
The Student’s t-test was performed to determine the statistical difference in
friction before and after surface modification.
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Tensile Test for Silicone Stripes
The stress-stretch relationship (S-S relationship) was obtained by using an Instron
machine (model 5542) equipped with 0.5 kN load cell, having 651 mm vertical test space.
The 5 mm wide, 50 mm long Sylgard 184 and LIM 6030 silicone strips with average
thickness of 0.5± 0.06 and 0.5± 0.02 mm, respectively, were prepared for the tensile test.
All the specimens (three specimens for each group) were subjected to the test at a cross-
speed rate of 30 mm/min, and the S-S relationship of the silicone stripes were compared
with that of the human MCA from autopsy which was performed quasi-statically at a
strain rate of about 0.05 s-1 144.
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Results
The anatomy of the three cerebral vessels from patient 1 (PA1), patient 2 (PA2)
and patient 3 (PA3) were shown in Figure 2-5 (a) through (c) having siphons with an AC
ranging from 0.23 to 0.64 mm-1. PA1, PA2 and PA3 were selected to illustrate mild,
moderate and severe curvature, respectively, of the ICA siphon in our patient population.
Figure 2-5 Virtual cerebrovascular models showed ICA siphons with low (a), medium (b), and high (c)
curvature.
In the vessel characterization, the best-fit polynomial to smooth the original
centerline data was determined by minimizing the error between of the polynomial curve
and original centerline. Figure 2-6 showed that the total error decreases significantly up
to the tenth-order polynomial fit, followed by a more gradual decline. The smoothed
centerline was re-sampled before curvature calculation.
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Figure 2-6 The total error decreased significantly up to the tenth-order polynomial fit, followed by a
more gradual decline.
It was observed that the AC tended to increase with the decrease of the distance
between control points, and became stable when the distance was less than 0.1 mm. This
change was significant in the measurement of ICA siphon with severe tortuosity, whose
AC increased from 0.45 to 0.65 mm-1 when the distance decreased from 0.4 to 0.01 mm.
In this study, the polynomial curve was re-sampled to have points at constant 0.05 mm
intervals for curvature calculation. By using the 10th-order polynomial to smooth the
original centerline and giving control points with constant 0.05 mm intervals, the AC, arc
length and diameter from 20 patients were 0.34±0.12 mm-1, 21.86±4.24 mm and
4.17±0.64 mm for the left ICA siphon, respectively. For the right siphon, the AC, arc
length and diameter were 0.34±0.13 mm-1, 23.31±5.72 mm, and 4.12±0.44 mm,
41
respectively. In patient 18 (PA18),  the p values resulted from the Wilcoxon signed rank
test for comparisons in AC, length, and diameter were all greater than 0.05, indicating
each measured parameter of PA18 had no significant difference to the corresponding
median. The p-values were 0.24, 0.37, and 0.96 for the comparisons in AC, arc length
and diameter, respectively, of the left ICA siphon, and 0.72, 0.29, and 0.49, respectively,
for those of the right ICA siphon. This finding was only observed in PA18, and led us to
select PA18 as a representative model of the chosen patient population in this study. The
results of vessel characterization were shown in Figure 2-7.
Figure 2-7 (a) AC and (b) length and diameter of the left and right ICA siphons from 20 patients.
A computer mold consisting of a core-shell structure for silicone injection was
shown in Figure 2-8 (a). Silicone was infused into a mold (Fig 2-8 (b)), which contained
the vasculature of circle of Willis (CoW) from PA2 as the core (Fig 2-8 (c)). Removal of
the side braches and dissociation of artifactually fused vessels from the image
reconstruction was done in Mimics. Figure 2-8 (d) and (e) showed silicone replicas of the
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CoW from PA2 and the representative right ICA from PA18, respectively. Using this
batch manufacturing process, 6 vascular replicas were made from the virtual model in 92
hours at a material cost of $250. The capital equipment and software used in this study
were quite expensive; however, these tools were available at most universities and
medical device companies.
Figure 2-8 The virtual core-shell structure (a) was designed for the preparation of the physical ABS
model (b) which contained the CoW (c) as the core. After silicone was cured, the ABS
model (b) was dissolved in xylene, resulting in a transparent CoW silicone replica (d). By
using the same manufacturing process, a representative right ICA siphon was built from
PA18 (e).
The static and dynamic COF of Sylgard 184 and LIM 6030 with various number
of LSR coatings were given in Table 2-1. The best values were obtained with a single
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coating for Sylgard 184: COF reduces by 55%, with a minimum static COF of 0.334±
0.169, and dynamic COF of 0.312±0.174. For LIM 6030, a 47% reduction in COF was
achieved with 3 layers of LSR topcoat, resulting in a static COF of 0.719±0.121, and
dynamic COF of 0.683±0.120.
Table 2-1 Static and dynamic friction coefficients of Sylgard 184 and LIM 6030 samples for different
number of coatings
0 0.738±0.093 0.707±0.089 1.346±0.113 1.298±0.113
1
0.334±0.169
(p=0.0016)
0.312±0.174
(p=0.0019)
1.052±0.216
(p=0.0273)
1.026±0.222
(p=0.0435)
2
0.366±0.114
(p=0.0005)
0.312±0.108
(p=0.0002)
0.815±0.114
(p<0.0001)
0.765±0.098
(p<0.0001)
3
0.471±0.091
(p=0.0018)
0.416±0.090
(p=0.0009)
0.719±0.121
(p<0.0001)
0.683±0.120
(p<0.0001)
The friction coefficient was presented as mean ± standard deviation. The Student’s t-test was performed to compare
the mean friction coefficient of coated and uncoated groups.  The two-tailed p-value <0.05 indicated a significantly
statistical difference.
Static COF Dynamic COF
LIM 6030Sylgard 184
Static COF Dynamic COF
Silicone Type
Coating Number
The S-S relationship of LIM 6030 and Sylgard 184 were shown and compared
with that of the human MCA from autopsy obtained from the quasi-static test conducted
by Monson 144 in Figure 2-9. It was found that as human blood vessel, silicone rubber
exhibited a nonlinear S-S relationship. Moreover, at low stretch, the slope of the S-S
curve of LIM6030 was 0.67 MPa, similar to that of the MCA from autopsy (0.41 MPa).
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Figure 2-9 The S-S curves of Sylgard 184, LIM 6030, and human MCA from autopsy were compared.
At low stretch, the elastic property of LIM6030 was closer to that of MCA from autopsy.
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Discussion
A great deal of effort has been made on creating polymeric vascular models for
surgical simulation, interventional practice, and hemodynamic research in vitro.
Quantitating anatomic features of the arterial structures for disease or lesion prediction
and diagnosis has also been widely investigated. To our knowledge, no studies have yet
to apply the vessel characterization results to the replica manufacturing process. In this
work, the disclosed manufacturing process of replicas was developed based on a model
extracted from a characterized population of imaging datasets. This could be an even
more powerful technique in the future as image databases grow, allowing an investigator
to search for anatomy specific to a precise patient population for whom a given
endovascular device is intended.
The image editing flexibility during the post-processing not only refines the
vascular mesh, but also expands the applications of the silicone replicas. For instance,
small vessel branches such as ophthalmic arteries can be removed resulting in a clean
vasculature which contains only the interested structure like the CoW or ICA before
centerline construction. To smooth the centerline, the RMSE describes how well the
fitted curve matches the original data set. During the smoothing process, a high
polynomial order does not guarantee better fitting results and can lead to oscillations
between the data points. The tenth order polynomial had a RMSE of 0.1 for PA1 and PA2,
and 0.16 for PA3 and was chosen as a smoothed centerline. To take minor changes along
the vessel centerline into consideration, the curvature of every 0.05 mm segment was
46
measured and averaged.  The median of each vascular feature was used to select a
representative model in this study. The nonparameteric Wilcoxon signed rank test was
eligible to be applied to this small case series (20 patients), and had fewer assumptions
about the population distribution.
Arterial lumen replicas can be obtained from human cadavers127, 131. Postmortem
alterations, including the shrinkage of arterial trees, produced dimensional errors of the
in-vitro model. Using MRA data to acquire the geometry of the target vessels in our
proposed manufacturing method avoided this problem and provided flexibility during the
post-processing. It was mentioned in Ghazali’s study145 that the noninvasive, non-contrast
enhanced 3D TOF MRA was highly accurate in depicting the arterial segments of the
circle of Willis except the posterior communicating arteries, and the same observation
also applied to this study. The poor depiction of posterior communicating arteries could
be attributed to the saturation effect of slow flow and the flow parallel to the acquired
section plane in addition to the normal anatomical variations in which these vessels were
not present.
Other methods of replica construction have been used, such as that described by
Knox et al.128 where they created a reusable master mold of lumen replica based on the
computed tomography scan data from a live patient to reproduce wax lumen models. The
major difficulty of this technique was the fabrication of the master mold which required
an experienced mold maker, was a time-consuming and expensive process, and the
resulting mold was not easily modifiable to change the replica anatomy. Compared to
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Knox’s method, the construction of our core-shell structure was straightforward and
efficient. On average, a virtual core-shell mold can be completed in 20 minutes after
receiving the scan data, enabling reproducible manufacturing of replicas of any selected
configuration.
In Sugiu’s study131 , 4 to 6 thin layers of silicone liquid were manually painted
onto the wax lumen cast to simulate the vessel wall, however, the thickness and
uniformity of the coating were not stated. Seong et al. 130 fabricated rabbit aneurysm
replicas by using dip-spin method. The lumen cast polished by sand papers was dipped
into the silicone mixture, and then mounted on a spinning shaft to obtain a layer of
uniform silicone coating. The repeated coating procedure was time consuming and not
reproducible. The described methodology, involving batch construction of an infusion
mold and batch dissolution of the mold leaving behind an elastomeric vascular replica,
served to improve these limitations. The core-shell mold kept the consistency of the
replica dimensions, and saved time via the batch manufacturing. Due to the structural
constraint, hand polishing was not applicable to our core-shell mold. To smooth the
lumen surface, the mold was rinsed with xylene and 2-propanol alternately. This
procedure allowed xylene to gradually dissolve model material and effectively prevented
the core-shell structure from collapse.
Besides the soft replica described above, the rigid block model provided another
option for in vitro use. Wetzel et al. used the 3D printer with the resolution of the build
layer of 0.076 mm to form the wax copies of the vascular trees based on rotational
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angiography data. The wax model was embedded in clear silicone which was then cured
to form a solid block. The holes drilled in the silicone block drained the melted wax.
After evacuation of the wax, a transparent rigid model containing the vascular lumen
inside was prepared.  The major concern of this lost-wax technique was the fragility of
the wax which resulted in the breakage of the vessel branches smaller than 1 mm. By
using the method reported here, silicone vascular replicas with branches smaller than 0.5
mm were made.
A common concern for selecting silicone as a material for vascular replica
fabrication was its high friction. Surprisingly few attempts have been made to minimize
the resistance between silicone replicas and medical devices. So far, an alternative
material used to prepare vascular replica in the application of neurovascular modeling
was poly-vinyl alcohol (PVA)133. The high water content of PVA hydrogel gave the
vascular replica a naturally lubricated surface; however, the life of PVA replicas was
limited, depending on the rate of water evaporation. Aside from using PVA in
substitution for silicone, Parylene coating successfully reduced the COF of elastomers by
forming a thin layer of Parylene film which closely conformed to the substrate146. The
restriction of this coating method was the requirement of the coating system for vapor
deposition during the process which may increase the cost and restrain the popularity of
this technique. As compared to the aforesaid methods, LSR topcoat offered an easy and
efficient option for smoothing inner wall of silicone vascular model. The low viscosity
allowed LSR topcoat to easily flow through the long and tortuous model; furthermore, it
only took 10-30 minutes to cure one layer of coating.
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Rubber, like silicone, is generally amorphous, with few strong interactions
between molecules. When the tensile force is applied, the tangled molecules are pulled to
become stretched. In order to maintain the constant strain rate, additional force is needed
on the stretched, oriented molecules. When a vessel is subjected to a tensile force, the
elastin and collagen fibers significantly contribute to the low and high stiffness in the S-S
curve147.  The results from the tensile test in this study showed that the S-S relationship of
LIM 6030 was similar to that of human MCA from autopsy at low stretch. To make this
conclusion, it was necessary to clarify and discuss the potential differences between in
vivo and in vitro test condition.  The blood vessel wall is an anisotropic composite
material in general, and receives multi-directional stress in the physiological environment.
All specimens described herein were subjected to uniaxial tensile strength, and stretched
longitudinally until breakage. Therefore, the results may not be able to represent the
mechanical response in vivo.  Furthermore, the contribution from the surrounding tissue
to the mechanical response of the vessels to the load was not taken into consideration in
the in-vitro and ex-vivo study. Lastly, factors such as age, sex and disease history of
donor, type of vessel and strain rate may cause large variation in the S-S behavior for
biological materials. It is noteworthy that the cerebral arteries are significantly stiffer and
less stretchable before failure as compared to systemic arteries148.
The described technique provides an efficient method for representative replica
construction. However, there are technical difficulties which might be encountered while
preparing the silicone models. Bubble formation during silicone injection may cause
defects of the silicone replicas. High pressure required to infuse silicone liquid with high
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viscosity into the mold may cause core structure motion, resulting in variation in wall
thickness. Finally, more imaging data will need to be reviewed to create a more realistic
environment for medical device testing, endovascular training and in vitro hemodynamic
studies.
Conclusion
A small batch manufacturing process was introduced in this study to generate
smooth, transparent, population based, anatomically accurate silicone cerebrovascular
replicas.  Importantly, this batch process allowed for reproducible replica generation. The
manufacturing process for each silicone replica required 15.5 hours.
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Chapter III: Ex-Vivo Modeling of Cerebral Emboli-Mimicking Clots
Abstract
Mechanical behavior of the embolus is one of the key factors that determine the
efficacy of thrombectomy devices. The goal of this study is to characterize the
mechanical properties and composition of thromboemboli from clinical cases as
compared to commonly used EAs.
Clinical thromboemboli were obtained from patients with AIS by using aspiration
devices and from carotid atherosclerotic plaques harvested during endarterectomy. On the
bench, EAs commonly described in the literature were created from various blood donor
species (human, porcine and bovine) with and without the addition of thrombin and
barium sulfate. Stiffness and elasticity of the specimens were monitored with dynamic
mechanical analyzer (DMA). Scanning electron microscopy (SEM) and histological
analyses were performed to investigate the ultrastructure and composition of the
specimens.
Of the clinical specimens, calcified thromboemboli showed the highest stiffness
followed by those containing cholesterol crystals. The softest clot material was obtained
from AIS patients and was found to be mainly composed of fibrin and erythrocytes. Of
the EAs created in the lab, bovine EAs presented the highest stiffness. Addition of
thrombin resulted in increases in stiffness and elasticity of human and porcine EAs. The
presence of barium sulfate significantly reduced the elasticity of EAs. The stiffness and
elasticity of the cerebral emboli analyzed in this study showed no significant differences
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with those of the recalcified porcine EAs and thrombin-induced (5 NIHU/ml blood)
human EAs. Stiffness of the carotid endarterectomies (CEA) specimens was similar with
that of the bovine EAs and thrombin induced porcine EAs.
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Introduction
With growing experience of penumbral imaging for patient selection and newer
more effective mechanical recanalization devices, alternative endovascular therapy for
AIS has become a viable treatment option149. There are presently two devices available in
the United States for thrombectomy in acute ischemic stroke and many other technologies
under evaluation. These devices produce recanalization, defined using the thrombolysis
in myocardial infarction (TIMI) score applied to catheter angiography studies98, 100, from
50% to 82% of cases. Currently, it is poorly understood what variables predict successful
recanalization. Characterization of the embolus may be helpful in device selection and
development.
In preclinical characterization of thrombectomy device technology, efficacy  and
safety are measured in large animal or in vitro vascular occlusion models150-153 with
endpoints such as number of thrombectomy attempts, the amount of EA removed from
the occlusion site, and the risk of distal embolic shower150, 151, 154-156. All of these
parameters are significantly affected by the mechanical properties of the EAs, an often
overlooked component of the testing system.  In the literature, many protocols to
manufacture EAs exist and common variables include the donor species, concentration of
thrombin and radiopaque additive such as barium sulfate118, 151, 155-158. Species differences
in blood chemical composition, hematological values159-162, thrombin effects on
coagulation profile163, functional structure of coagulation proteins164, 165,166, 167, blood
coagulation mechanism168 and pH and ionic strength of the clotting environment169,170-
54
173influence the structure (diameter, length and branch point density of the fibrin fibers174)
and mechanical properties of the clotting materials in-vitro160, 172, 175-177. The mechanical
properties of EAs formed in-vitro are normally investigated by using rheometry178-180,
thrombelastography181, 182, and atomic force microscopy/fluorescence microscopy183.
The aforesaid findings lead to the hypothesis that commonly employed EAs have
different mechanical properties, and currently we do not know how they relate to human
sources of thromboemboli that cause stroke. Human sources of thromboemboli are
normally classified into three different types: white, red thrombus, and disseminated
fibrin deposit184. The composition of all three varies in the relative amounts of fibrin,
platelets and erythrocytes. The platelet and fibrin-rich white thrombus usually forms at
injured vessel wall, particularly in areas where blood flow is fast, whereas the fibrin and
erythrocyte-rich red thrombus may form in the venous system where the blood flow is
retarded. Fibrin clots, containing some white and red blood cells but no platelets, can be
found in small cerebral arteries of approximately one third of the patients with recent
embolic infarcts165. The highly variable nature of these thrombi creates a challenge to the
study of revascularization devices and drugs. Two recent studies analyzed the
composition of emboli retrieved from the stroke patients. Marder et al. first
systematically analyzed thrombi retrieved from ICA and MCA of patients with AIS, and
discovered that 75 % of thromboemboli had random fibrin and platelet deposits
interspersed with nucleated cells and confined erythrocyte-rich regions185. Another
histological analysis was performed on thrombi extracted from 5 patients with AIS by
using the MERCI retriever186 and the results showed that most thrombi had a variable
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composition of fibrin and red blood cells. Moreover, different degrees of calcification
were seen in 2 thrombi. The abovementioned studies substantiated the structural and
compositional variations between the in-vivo emboli and in-vitro EAs; however, no
attempts have been made to characterize the mechanical properties of EAs and relate
them to thromboemboli from patients.
The goal of this study is to explore the impact of the aforesaid variables on the
mechanical properties of the EAs commonly used in the lab; namely, 1. Stiffness --
ability to deform the EA and 2. Elasticity -- ability of the EA to return to its original
shape after deformation. Thereafter, mechanical properties of the EAs are compared with
those of the thromboemboli retrieved from patients.
Materials and Methods
Preparation of Embolus Analogues
Our literature review showed that human, porcine and bovine blood donors are
commonly used for EA preparation. EAs were generated by spontaneous coagulation (no
thrombin added)156 or created by thrombin-induced clotting151. The anticoagulant citrate
dextrose solution (ACD)-containing blood was either recalcified by adding calcium150, 155
or clotted with addition of thrombin (2.5 NIHU/ml blood) and barium sulfate (1g/10 ml
blood)158. Barium sulfate is commonly added to the clot matrix to make the EA visible
under X-ray187-189. In this study, the effects of thrombin (0, 2.5, and 5 NIHU/ml blood)
and barium sulfate (0 and 1g/10 ml blood) on the stiffness and elasticity of the bovine,
porcine and human EAs were studied.
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Without the presence of thrombin, spontaneous coagulation was initiated by
mixing bovine, porcine or human whole blood/ACD mixture (10:1) and calcium chloride
(97 mmol/L) at a 5:1 ratio. Based on the species divergence of structure and function in
fibrinogen177 and specificity of the thrombin-fibrinogen interaction176, bovine thrombin
(Sigma T-7513) was used to initiate fibrin formation in bovine and porcine EAs; whereas,
human thrombin (Sigma T-6884) was employed in human blood samples. Thrombin-
induced clotting was conducted by simultaneously injecting whole blood/ACD mixture
(10:1) and calcium chloride (97 mmol/L)/thrombin solution (1NIHU thrombin/4 µl
solution) into silicone tubing (I.D. 6.35 mm) to give blood mixtures with final thrombin
concentration of 5 and 2.5 NIHU/ml blood. Before injection, silicone tubing was rinsed
with 70% alcohol followed by 0.9% saline. The radio-opaque EA was created by adding
1g barium sulfate into the 10 ml blood mixture which had a thrombin concentration of 2.5
NIHU/ml blood158. All EAs were aged in saline at room temperature for one day prior to
characterization.
Collection of Thrombi from Patients
All human specimens were collected with approval from our Institutional Review
Board. Nine emboli were obtained by aspiration from the ICA or MCA of 4 stroke
patients (Figure 3-1 (a) to (c)).
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Figure 3-1 Patient presented with an AIS due to MCA occlusion (a, arrow). The embolus was
aspirated from the MCA with the Penumbra system and successful recanalization was
achieved (b). Examples of material extracted from stroke patients by aspiration (c).
Due to the fact that debris from atherosclerotic plaques and atrial fibrillation are
well-documented as important sources of emboli to cause AIS190,191, 26 atherosclerotic
plaques removed during CEA and 1 atrial appendage were collected. Materials which
were loosely attached to the lumen of the plaques and red thrombi which were removed
from under the fibrous cap were considered as the potential sources of cerebral emboli.
The materials were harvested from the plaques for analysis. After careful examination
under the microscope, a total of 13 potential sources of emboli were extracted from 7
asymptomatic and 1 symptomatic plaques (8 patients). No thromboemboli were
recovered from the atrial appendage. Clinical data of 12 patients and details of emboli are
provided in Table 3-1, where the tested emboli were numbered by the procedure type (C:
carotid endarterectomy, A: aspiration in acute ischemic stroke) followed by an integer
denoting the order in which the embolus was obtained. In order to avoid confusion, the
term “thromboemboli” henceforth refers to emboli obtained from this patient population.
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Mechanical Characterization
DMA (Q800, TA Instruments, New Castle, DE) which had a force resolution of
0.00001 N, and a strain resolution of 1 nanometer was used to explore the stiffness and
elasticity of the emboli and EAs. All the mechanical examinations were conducted using
a submersion compression clamp within saline at 37oC. The EAs were cut to have a
height of 2 mm, and a caliper having a resolution of 0.1 mm was used to measure the
diameter of the EA. The emboli retrieved from patients had an irregular shape and were
carefully trimmed using micro-scissors and double-edged razor blades under the light
microscope to have a height between 1 and 2 mm. To prevent test material (emboli or
EAs) from slipping, 220-grit sandpaper was adhered to the compression disk.
In the controlled force mode, the test materials were first subjected to a preload
force of 0.0001N, followed by a compression force ramp from 0.0001 N to 15 N at a rate
of 0.5 N/min. The deformation of the test material caused by the compression stress was
used to produce an engineering S-S curve. Onset point, the intersection of the initial and
final tangent lines, was recorded to determined the strain at which a change in the slope
of the S-S curve occurred. Stress was defined as force over surface area, and strain was
referred to deformation in height over original height. To quantitatively describe the
deformation of the test material under the compression force which simulated the large
strain induced by the thrombectomy devices during treatment, stress variation over a
range of strain (the slope of the S-S curve) was calculated. The secant modulus (E intitial
strain-end strain) is the slope of a line formed by connecting the point on the S-S curve from
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defined initial to end strains. As such, E intitial strain-end strain is an indication of the stiffness of
the material. The area under the S-S curve, which represents the energy required to
deform the material, was also calculated.
In the stress-relaxation mode, the test materials were subjected to an initial strain
of 60 % for 5 min, followed by a recovery period of 15 min. The strain recovery (%), a
measure of material elasticity, was acquired.
Histological Assessment
Emboli and EAs were fixed in a 10 % buffered formalin solution for 48 hours.
Specimens were then embedded in paraffin wax and cut into 5μm sections. Sections were
dewaxed and hydrated to distilled water in preparation for a modified version of the
Martius Scarlet Blue (MSB) method for staining fibrin, collagen and erythrocytes192.
Alternating sections were stained with Hematoxylin and Eosin (H&E).
SEM
Emboli and EAs were fixed with 2.5% glutaraldehyde, and dehydrated in series of
ethanol concentrations up to 100 %. To observe the interior of the emboli and EAs,
samples were frozen in liquid nitrogen and fractured. Samples were critical-point-dried,
mounted, and sputter-coated with iridium for SEM observation. Energy dispersive X-ray
spectroscopy (EDS) was performed on two samples.
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Statistical Analysis
Data were presented as mean ± standard error. Unpaired t-test was performed to
compare the means of the non-calcified plaque materials and cerebral emboli retrieved
from the AIS patients. One-way analysis of variance followed by Dunnett's or Tukey's
post test was used to determine significance between patients’ emboli (control) and EAs
or between the EAs, respectively. Statistical significance was set at p<0.05. Statistical
analysis was performed using GraphPad Prism (GraphPad Software Inc., San Diego, CA).
Results
The histology findings revealed that the EAs were mainly composed of
homogeneously dispersed erythrocytes with several interspersed fibrin bands (Figure 3-2
(a)); moreover, a layer of dense fibrin mesh was formed on the outer surface of the EA
that was against the silicone tubing (Figure 3-2(b)). The average onset point of these
erythrocyte-rich EAs analyzed under DMA controlled force mode (n=65) was 89.11±0.55
%. In this study, two secant moduli, E0-75% and E75-95%, were calculated to describe
stiffness of EA.
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Figure 3-2 (a) The EA was mainly composed of erythrocytes (shown in yellow) with fibrin clumps
dispersed in it (arrows, bar=10 microns). (b) A layer of fibrin was formed on the surface
of the EA against the silicone tubing (asterisk, bar=10 microns).
Overall, bovine EAs showed the highest stiffness followed by porcine and human
EAs (Figure 3-3 (a-b) and (e-f)). Without addition of thrombin, E0-75% and E75-95% of
bovine EAs were statistically higher than those of porcine and human EAs (p< 0.05).
However, there was no significant difference in stiffness between EAs made from porcine
and human. Increases in stiffness and elasticity of human and porcine EAs were found
when thrombin was present at a concentration of 5 NIHU/ ml blood (p<0.05). In the
absence of thrombin and barium sulfate, the bovine EAs had strain recovery of 30.28
±2.48 %, whereas strain recovery in human blood derived EAs was unmeasurable due to
their fragile nature. Elasticity of the thrombin-induced porcine EAs was higher than that
of the thrombin-induced human EAs (p<0.05) (Figure 3-3 (c)). As compared to the
counterparts of the bovine and human EAs, thrombin-induced porcine EAs retracted the
most (Figure 3-3 (d)). A significant decrease in elasticity (p<0.05) were found in all EAs
containing barium sulfate (Figure 3-3 (g), Figure 3-4 (a) and (b)). With the presence of
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barium sulfate, the area between initial to 95 % strain under the S-S curve tended to
increase (Figure 3-3 (h)).
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Figure 3-3 Impacts of thrombin and barium sulfate on the stiffness (E0-75% and E75-95%), strain
recovery and diameter of the EAs were shown in (a) to (g).  An increase in area under the
stress-strain curve was observed with the presence of barium sulfate (h).
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Figure 3-4 (a) A secondary electron image of the bovine EA with barium sulfate (x 20,000) (b) a
mixed secondary and backscattered electron image of barium sulfate agglomerates (x
20,000).
From September 2009 to May 2010, 26 atherosclerotic plaques, 1 atrial
appendage and cerebral emboli (from 4 AIS patients) were collected from 31 patients.
With careful examination under microscope, 13 thrombi were harvested from 8 plaques
collected at CEA and no emboli were found in the atrial appendage. Along with 9
cerebral emboli from the AIS patients, a total of 22 specimens from 12 patients (mean
age, 70 years) with an average thickness of 1.43±0.11 mm and surface area of 6.22 ±0.97
mm2 were characterized (Table 3-1).
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Table 3-1 Demographic data of 12 patients and characteristics of 22 emboli.
No.† Site Source Appearance & Composition
C1 ICA
excessive hrombus removed
 from he plaque
red, ery hrocyte-rich
C2 ICA off-white, partially calcified and fibrin-rich
C3 ICA pink, platelet and fibrin-rich
C4 ICA pink, platelet and fibrin-rich
C5 ICA red, platelet and fibrin-rich
C6 ICA off-white, fibrin-rich wi h cholesterol crystals
4 M 64
high grade stenosis of he right ICA origin
 with intraluminal hrombus of he entire right ICA, M1,
and proximal M2 divisions of he right MCA
aspiration A1 MCA
artery-artery embolus associated wi h ipsilateral carotid
disease
red, fibrin, erythrocyte, platelet and leukocyte-rich
5 M 65
right ICA origin >90% segmental stenosis with
intraluminal thrombi at the proximal end and distal
end of the lesion. Occlusion of he right MCA
aspiration A2 ICA cardiocembolic
red, fibrin, erythrocyte, platelet and leukocyte-rich
6 M 79 asymptoma ic right ICA stenosis CEA C7 ICA yellow-white, calcium phosphates
C8 ICA
C9 ICA
C10 ICA red, fibrin, erythrocyte and platelet-rich
C11 ICA red, fibrin, erythrocyte and platelet-rich
9 F 78 MCA occlusion aspiration A3 MCA cardiocembolic red, fibrin, erythrocyte, platelet and leukocyte-rich
11 M 53 symptoma ic ICA stenosis CEA C12 ICA hrombi (1cm in leng h) loosely attached to fatty streak red, fibrin, ery hrocyte and leukocyte-rich
12 M 81 asymptoma ic ICA stenosis CEA C13 ICA hrombi loosely attached to luminal surface dark red, lipid-rich
M MCAA4-A9
CEA
CEA
CEA
74 asymptoma ic right ICA stenosis
F
red, fibrin, erythrocyte, platelet and leukocyte-richMCA occlusion
asymptoma ic left ICA stenosis
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ProcedurePretreatment Diagnosis
hrombi loosely attached to luminal surface dark red, lipid, packed fibrin, fibronec in and cells
† The sample number (No.) is determined by the procedure type (C: caro id endarterectomy; A: aspiration in acute ischemic stroke) followed by an integer denoting he order in which it was obtained.
77 asymptoma ic left ICA stenosis
3 M 68 asymptoma ic ICA stenosis
CEA
CEA
aspiration
1 M 79 asymptoma ic left ICA stenosis
Pa ient Sex Age
10
7 M
2
cardiocembolic
8 M 72
Specimen
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Emboli obtained from the patients can be classified into three categories; (1)
calcified emboli (Figure 3-5 (a)) (2) aged emboli (Figure 3-5 (b)) and (3) red emboli
(Figure 3-5 (c)), according to their composition and mechanical properties.
Figure 3-5 Thrombi containing calcified materials (a), cholesterol-rich materials (b) and fibrin and
erythrocyte materials (c) were found in the atherosclerotic plaques.
The calcified emboli (C2 and C7, Table 3-1) had large amounts of Ca/P apatite
(Figure 3-6 (a)). In Figure 3-6 (b) and (c), the SEM and histology results showed that the
aged emboli had highly compacted structure, and consisted of old fibrin, adhesive
proteins, connective tissue and other cells such as erythrocytes and platelets. The features
of red emboli are presented in Figure 3-6 (d) to (f). Aggregation of erythrocytes (yellow
in Figure 3-6 (d)) was trapped in the fibrin network. Leukocytes were dispersed
throughout the embolus (Figure 3-6 (e)). At higher magnification, the histology findings
further indicated that the cellular elements found in the cerebral emboli retrieved from the
AIS patients were arranged in a specific layer-by-layer pattern (Figure 3-6 (f)).
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Figure 3-6 Morphological features and composition of a variety of emboli from patients. (a) A
calcified embolus. Ca/P apatite was detected by the EDS scan (inset) (b) An aged embolus
had a compact structure with fissures which were occupied by the cholesterol crystals
(arrows) and fibrin at the edge of the specimen (asterisk). The SEM findings were related
to the MSB result (x20, bar=100 microns) shown in (c). (d) MSB results showed that a
red embolus was mainly composed of fibrin and erythrocytes (old fibrin in blue,
erythrocytes in yellow and erythrocyte/fibrin mixture in red) (x2, bar=1mm). (e)
Photomicrograph of a red embolus retrieved from the stroke patient (H&E x10, bar= 200
microns) revealed that the leucocytes were distributed throughout the embolus. (f) At x10,
it was found that erythrocytes and fibrin strands were arranged in a layer-by-layer
manner in the red embolus (MSB, bar= 200 microns).
The high stiffness of the calcified emboli was identified in Figure 3-7. The S-S
curves of the calcified emboli (black curves) showed early onset point (42.90±8.03 %)
and smaller strain under a 15 N force (the end of the test), and demonstrated that higher
stress was required to cause 45 % strain (e.g., C7 in Figure 3-7) on calcified emboli as
compared to other emboli. To achieve a fair comparison, E0-45% was used to make
comparisons between calcified and non-calcified materials; on the other hand, for
comparisons made between non-calcified emboli with high strain, E0-75% and E75-95% were
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applied. Late onset point (85.39±0.85 %) and large strain under a 15 N force were seen
on the aged emboli (purple curves) collected during CEA, which were loosely attached to
the vessel lumen and had a dark reddish-brown color. The stiffness of the aged emboli
(E0-45%= 0.17±0.039 MPa) fell between that of the calcified emboli (E0-45%= 0.63±0.38
MPa) and red emboli (E0-45%= 0.026±0.0026 MPa). The red emboli had the latest onset
point (91.29±0.82 %) and largest strain upon loading with 15 N.
Figure 3-7 The engineering S-S curves show that at the end of the test, a 15 N force causes a 45.7 %
strain to a highly calcified embolus (black solid line) and a 64.4 % strain to a partially
calcified embolus (black dashed line). It is noted that the same compression force can
result in a higher strain (> 80%) on the other emboli.
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The average E0-75% and E75-95% of the emboli retrieved from the AIS patients were
0.04±0.01 MPa and 0.43±0.06 MPa, respectively, whereas those of  the potential sources
of non-calcified emboli obtained from the CEA plaques were 0.11±0.037 MPa and
1.60±0.50 MPa, respectively. It should be noted that large variations in E0-75% and E75-95%
were seen in the CEA emboli due to the high variability in the composition as previously
described (Figure 3-8). Stress relaxation tests revealed an average strain recovery of
32.86±2.33 %.
Figure 3-8 Comparisons of potential sources of emboli (CEA) and emboli those caused AIS in terms
of E0-75% and E75-95%. Large variations were observed in the CEA groups.
A series of comparisons between different types of EAs and emboli obtained
showed recalcified porcine EAs , thrombin-induced (5 NIHU/ml blood) human EAs are
similar to cerebral emboli retrieved from the AIS patients in terms of stiffness and
elasticity (p>0.05) (Figure 3-9 (a) to (c)). The potential sources of the emboli collected at
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CEA, bovine EAs and thrombin induced porcine EAs had no significant differences in
stiffness (Figure 3-9 (d) and (e)).
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Figure3-9 A series of comparisons in terms of stiffness and elasticity between different types of EAs
and emboli obtained from AIS ((a) to (c)) and during CEA ((d) and (e)).
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Discussion
Embolus characteristics in terms of mechanical properties, composition and
structure are important in the endovascular treatment of AIS. In prior research, EA
stiffness was considered as a variable to create embolic occlusion in canine models for
evaluation of recanalization via stent implantation193. In a more recent investigation,
manual elongation tests were performed using forceps to stretch EAs153. In this present
work, stiffness and elasticity of the EAs and emboli were quantitatively measured and
compared to the clinical thromboemboli they are intended to represent. DMA
compression test is ideal for characterization of soft viscoelastic materials, such as emboli
and their analogues. As the name indicates, the mechanical responses of the viscoelastic
materials are a mixture of viscous and elastic behavior. A complete strain recovery of an
elastic material, like a spring, can be observed after removing the applied stress. On the
contrary, viscous deformation is nonrecoverable (permanent). In the thrombectomy
treatments, strain recovery (as an indication of elasticity) and stiffness of the emboli are
important material characteristics to predict the safety and efficacy of the devices and
procedure.
EAs prepared by using blood from different species produced different stiffness
and elasticity, and these variations can be explained from the following considerations.
Fibrin is the product formed after fibrinogen polymerization, and the major constituent of
emboli and EAs. Fibrin fiber diameter and branchpoint densities increase as the
fibrinogen concentration increases from 0.3 to 0.6 g/dl 175, and the stiffness of the EAs is
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proportional to the starting fibrinogen concentration. The results of the mechanical
characterizations in this study are consistent with the abovementioned findings. The
average fibrinogen concentration in bovine plasma is between 0.5-0.7 g/dl, which is
higher than that in pig (0.1-0.5 g/dl) and human (0.2-0.4 g/dl) plasma. Consequently, the
bovine EAs showed higher E0-75% and E75-95% as compared to the porcine and human EAs.
Significant increases (p<0.05) in stiffness and strain recovery of porcine EAs induced by
adding 5NIHU/ml thrombin (Figure 3-3) were attributed to the reactive blood coagulation
mechanism of the porcine blood as well as the presence of large amount of platelets in
porcine plasma (250-500 103/mm3 for porcine versus 150-450 103/mm for human).
Thrombin-activated platelets are known to be essential contributors to the EA elasticity
and retraction180.
Aggregation of barium sulfate was observed under SEM (Figure 3-4), indicating
its low solubility in blood. Use of thrombin is suggested in the preparation of barium
sulfate impregnated EAs to enable rapid formation of the fibrin matrix that traps the
particles of barium sulfate enabling a more homogenous distribution. Influences of
barium sulfate aggregations on the fibrin network structure such as pore size, density and
branch points were not studied in this work; however, the inelastic nature of the barium
sulfate led to a significant decrease in the strain recovery of EAs. As compared to the
recalcified EAs, it was found that the S-S curves of the barium sulfate-containing EAs
showed a gradual change in slope, and had a higher elongation. Additionally, the area
between initial to 95 % strain under the S-S curve of the barium sulfate-containing EAs
tended to increase, indicating that these materials became tougher (higher energy to
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break). In the work by Gralla et al, barium sulfate containing EAs were used to  evaluate
the efficacy of the Catch device (Balt, Montmorency, France) in the occluded extracranial
vessels of swine158. The authors describe 20 unsuccessful recanalization attempts
performed with the Catch device where the applied force from the aspiration system
initially elongated the EA, but was not sufficient to retrieve or fragment the EAs. The
results from our present study show that barium sulfate doped porcine EAs are “elastic
and tough” as compared to the emboli observed clinically, which may be in part
responsible for the failure of the Catch device in these experiments.
The elasticity of the calcified emboli was not available in this study. The force
required to cause 60 % strain on the calcified emboli exceeded the limitation of our
equipment due to the high stiffness of the calcified emboli. The aged emboli had highly
compact structure and the dark reddish-brown color. When these samples were prepared
for DMA sample preparation, a lack of elasticity was observed, which could be
associated with the protein degradation of these aged materials. This experience was
concordant with the previous findings that the aged thrombi provided little resistant to
mechanical thrombectomy194. As with recalcified porcine EAs and thrombin-induced
human EAs, the red emboli showed higher elasticity with an average strain recovery of
32.86±2.33 %.
Our study was limited by a unidirectional compression test to explore the material
properties anisotropic specimens. However, the small size of the thrombi makes it
difficult to measure the hardness and elasticity in different directions. It is important to
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note: (1) the modulus presented in this study is only for comparison due to the use of the
sandpaper, and (2) unlike polymer and other synthetic materials, the stiffness of the
biological tissue may depend on strain. Despite these limitations, we were able to fully
characterize common EAs used in the laboratory and compare them with the
thromboemboli they are intended to represent. Precise characterization of EAs is an
important element to proper preclinical evaluation of thrombectomy devices.
Summary
Differences in structure and composition were observed between EAs and human
thromboemboli. Recalcified porcine EAs and thrombin-induced (5 NIHU/ml blood)
human EAs were similar with cerebral emboli retrieved from patients with AIS in terms
of stiffness and elasticity. There was no significant variation between the stiffness of the
material collected at CEA and bovine or thrombin induced procine EAs. Addition of
barium sulfate for radioopacity in the EAs dramatically reduces the elasticity. Fully
characterized EAs with known mechanical properties are now available for preclinical
evaluation of thrombectomy devices.
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Chapter IV: A Novel Model System of Cerebrovascular Occlusion for Preclinical
Assessment of Mechanical Endovascular Treatment of Acute Ischemic Stroke
Abstract
The purpose of this study was to design an in vitro model system of
cerebrovascular occlusion that allows realistic testing of mechanical thrombectomy
devices.
The proposed model system was composed of a human vascular replica, an
embolus analogue, and physiological hemodynamic conditions. The MERCI L5 Retriever,
Penumbra system 054, Enterprise stent, and ultrasound waveguide device were evaluated
in terms of the efficacy and safety. The primary efficacy endpoint was the amount of
blood flow restored, and the secondary endpoint was the ability to achieve recanalization.
The primary safety endpoint was an analysis of clot fragments and their size distribution.
The Penumbra system achieved the highest recanalization rate (80%) followed by
the MERCI L5 Retriever (67%), Enterprise stent (17%) and ultrasound waveguide device
(0%). Temporary flow restoration (29.28% ±6.42%) was recorded when the stent was
self-expanded during the procedure. No EA fragments had dimension greater than
1000µm, and mean size of the small and large particles were between 32 to 40 µm and
219 to 273 µm, respectively, depending on the device used. The recanalization rate of the
thrombectomy device was related to the ability of the device to capture the EA during
removal of the device and the geometry of the vascular replica. The risk of the embolic
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shower was influenced by the mechanical properties of the EA and the mechanism of
action for the thrombectomy device.
Introduction
A model system of cerebrovascular occlusion is essential for evaluation of the
mechanical thrombectomy devices. The models built for device testing in the previous
studies were mostly composed of a straight-tubing system154, 155, 195, 196 filled with
water197 or saline151, 195, and occlusion sites created by using different kinds of EAs. Prior
work focused on the consistency of the EA models156, or laid emphasis on the geometry
of the vascular replica150, while other investigators stressed the hemodynamic
simulation154. What seems to be lacking; however, is a reproducible and physiologically
realistic model system that enlists all the aforesaid elements.
Mechanical removal of thromboembolic materials from cerebral arteries by using
FDA-approved devices, the MERCI and Penumbra systems, has been widely-investigated
in extracranial vascular occlusion animal models and in the clinical arena. The results
showed that ,without adjunctive therapies, the recanalization rate (57.3% for MERCI L5
Retriever98) and clinical outcome (29% mRS ≤ 2 after 90 days with the Penumbra
treatment100) of these devices still could be improved. Testing these devices in an
experimental model not only provides information on EA-device interaction during the
procedure but also helps device selection in different clinical scenarios.
Unlike balloon expandable stents, the flexible self-expanding nitinol stents are
easier to be navigated in the tortuous cerebrovasculature, and deployed at lower radial
78
force108, 198, 199. The favorable outcome presented in the first FDA-approved prospective
trial of primary intracranial stenting for acute stroke109 suggested the potential utility of
the self-expanding stent in the treatment of AIS. Ultrasonically driven waveguide has
been shown to break thrombus into micro particles by cavitation and is currently FDA
approved for thrombus ablation applications in the peripheral vasculature155. The
application of waveguide ultrasound technique has tended to expand to the ablation of the
thrombotic materials in cerebral arteries where the vessel geometry is more complex and
tortuous. The success of this design may provide another option for physicians to treat
patients with acute ischemic stroke.
The goal of this study is to build a reproducible occlusion model system
incorporating human ICA/MCA vascular replica, blood- mimicking solution,
physiological hemodynamic conditions, and a clinically relevant embolus analogue for
evaluation of the aforesaid 4 endovascular devices.
Materials and Methods
Construction of Silicone Replica
The silicone ICA/MCA replica with a representative ICA siphon in terms of
curvature, diameter, and length was selected from 20 patients and built by using a small-
batch manufacturing process, as described in Chapter 2200. The AC, diameter, and length
of the ICA siphon were 0.36 mm-1, 4.21 mm, and 20.62 mm, respectively. The MRA
dataset provided the geometry of the vasculature, and the image post-processing was
performed in Mimics (Materialise, Leuven, Belgium). The virtual model was modified to
79
include only the ICA, M1 and M2 divisions. The two M2 divisions were artificially
designed to rejoin distally having a fenestrated appearance to produce a single output that
simplifies the flow rig. This simplified model was restricted to the critical vascular
anatomy relevant to thrombectomy testing in an MCA occlusion by removal of branches
such as the ophthalmic and anterior cerebral arteries. A core-shell mold was created in
Magics (Materialise, Leuven, Belgium) based on the geometry of the vasculature
reconstructed in Mimics for silicone (Sylgard 184, Dow Corning, Midland MI) infusion.
A transparent and flexible silicone replica was obtained by dissolving the core-shell mold
in xylene after curing. To reduce the friction between the device and the silicone replica,
the inner wall of the resulting replica was lubricated by coating a layer of LSR topcoat
(Momentive Performance Materials, Albany NY).
Flow Loop Design
The ICA/MCA replica was set in an acrylic box (20 cm × 13 cm × 10 cm), and
the orientation of the replica was adjusted and maintained by rotating and sliding the
connecting tubes (inner diameter = 4.8 mm) that served as the inlet and outlets to the
vascular replica. The acrylic box containing the silicone replica was connected to a flow
loop which contained a programmable piston pump (Shelley Medical Imaging
Technologies, Ontario, Toronto, Canada), blood-mimicking fluid (60/40 water/glycerin)
reservoir, and starling resistor chambers. A filter funnel employing a filter with a pore
size of 54 microns was attached to the blood-mimicking fluid reservoir in an effort to
reduce particle introduction into the system. A physiologically realistic pressure
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waveform was generated by the pump to produce fluid velocities similar to those
observed in the human carotid arteries. The Starling resistor adjusted the resistance so
that the pressure was controlled. The data acquisition system (Dewetron Inc, Charlestown,
RI) was equipped with an analog-to-digital converter, and incorporated the synchronized
video captured by a digital camcorder. Analog channels were displayed in raw voltage,
and the math channels were be used to calculate items such as corrected flow and
pressure.
The schematic illustration of the flow loop is presented in Figure 4-1. The flow of
the filtered blood-mimicking fluid pumped out from the reservoir simulated the CCA
flow. The mock CCA divided to mimic the external and internal carotid arteries, and the
latter was connected to the silicone ICA/MCA replica. Collateral flow derived from the
ECA joined distal to the ICA/MCA model to maintain a realistic pressure gradient. The
flow sensors (Transonic Systems Inc., Ithaca, NY) measured the CCA and MCA flow,
and pressure transducers (Validyne Engineering, Northridge, CA) which have a good
dynamic response, were used to record the proximal (P1 in Figure 4-1) and distal MCA
(P2 in Figure 4-1) pressure. The blood-mimicking fluid travelled through the ECA was
directed to a filtration system before re-entering the blood-mimicking fluid reservoir; on
the other hand, fluid travelled through the ICA was collected in an empty container for
particle analysis.
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Figure 4-1 The schematic illustration of the flow loop. CCA was connected to the flow pump, and
divided to form ICA and ECA. Collateral flow was diverted from the ECA region to
distal MCA.
Preparation of Emboli and Creation of Occlusion
The radio-opaque bovine EA, mimicking the thrombi extracted from the
atherosclerotic plaques, was prepared by thrombin-induced clotting for device testing as
described in Chapter 3. Briefly, the EA was created by mixing thrombin/CaCl2 solution
and barium sulfate/ bovine blood mixture (1g barium sulfate/10 ml blood) at a thrombin
concentration of 2.5 NIHU/ml blood. The concentrations of the thrombin and barium
P1
P2
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sulfate used for EA preparation in this work were also commonly used in in-vitro
modeling of EAs to create the vascular occlusion in animal models for thrombectomy
device testing153, 157.
Bovine EA was formed in silicone tubing with an inner diameter of 4.76 mm one
day prior to the experiment, and it was cut by a scalpel to have a length of 1cm for
creation of in-vitro occlusion. Weight of the bovine EA was measured by a scale with a
resolution of 0.1 mg. EA was injected into the flow loop via a separate entry close to the
silicone replica, and the pressure and flow changes caused by the occlusion were
recorded.
Thrombectomy Devices and Procedures
All procedures were performed under x-ray guidance (Allura FD20, Philips
Healthcare, Best the Netherlands).
The self-expandable stents, (Enterprise Vascular Reconstruction Device™
Codman Neurovascular, Raynham MA), with unconstrained stent length either of 28 or
37 mm and outer diameter of 4.5 mm were evaluated in this study (Figure 4-2). A 6Fr
guide catheter was placed proximal to the occlusion in the ICA, and delivered the
guidewire which was then softly advanced through the EA.  A microcatheter (Prowler
Plus, Codman Neurovascular) was navigated over the wire to the distal end of the
occlusive EA. The guidewire was withdrawn followed by stent deployment for EA
retrieval. The stent was deployed across the embolus and the expanded system was
slowly withdrawn in an effort to retrieve the EA.
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Figure 4-2 The Enterprise stent. The highly flexible stent is made of nitinol, and has a closed-cell
design which makes the stent partially retractable and allows repositioning201 (Courtesy
of Codman Neurovascular Inc., Miami, FL).
To deliver the MERCI Retriever L5, a 9 Fr balloon guide catheter was inserted
and positioned in the ICA. Navigation of the MERCI microcatheter 18L through the EA
was performed over the wire with fluoroscopic navigation. The guidewire was exchanged
for the MERCI Retriever L5, which was deployed beyond the occlusive EA. The
corkscrew-shaped retriever engaged the EA, and was pulled back into the guide catheter
with the microcatheter with proximal temporary balloon occlusion of the ICA. Vigorous
aspiration to the balloon guide catheter was applied by using a syringe.
The Penumbra system consisting of a reperfusion catheter 054, separator 054,
aspiration tubing and suction pump was set up for EA removal. An 8 Fr guide catheter
was positioned in the proximal ICA and the reperfusion catheter was advanced through it
to the proximal aspect of the bovine EA. The vacuum pump was operated and the
separator 054 was inserted into the reperfusion catheter. The side port of the rotating
hemostasis valve was connected to the aspiration tubing. During aspiration, the separator
was advanced and retracted to assist with EA removal.
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The ultrasonic endovascular system comprising an ultrasonic energy source,
transducer and ultra thin wire developed by OmniSonics Medical Technologies
(Wilmington, MA) was tested. A 6Fr guidecatheter was positioned in the ICA and
through this a 0.028” Hypertransit microcatheter (Codman Neurovascular) was
positioned across the occlusive embolus. The thrombectomy wire was delivered through
the microcatheter which was then withdrawn to expose the active section of the wire. The
ultrasonic transducer was coupled on the proximal end to the wire, which causes high-
frequency vibration to the distal active section. The mechanical motion of the active
section produced cavitation streaming that is necessary to fracture the fibrin matrix of the
embolus. The system was activated at a frequency of 150 kHz and a voltage of 300 mV
for 20 min.
Evaluation of Thrombectomy Treatments
A minimum of 5 experiments were carried out for each of 4 thrombectomy
devices.  To investigate the efficacy (ability to restore blood flow) of the tested devices
the location where the device was deployed, percentage of the remaining clot by weight
after the treatment, and percentage of flow restored were recorded. On the other hand, to
assess the safety (embolic shower protection) of the thrombectomy devices, particle size
analysis of the effluent following EA disruption was evaluated by using the Coulter
Principle (Multisizer 4 Coulter counter, Beckman Coulter, Inc., Brea, CA). After catheter
deployment, 400 mL blood-mimicking solution was collected as blank for particle
analysis, and the results were subtracted from the following tests. A 2000 µm aperture
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with a sensitivity range between 200 to 1600 µm and a 400 µm aperture which had a
sensitivity range between 8 to 320 µm were used to measure the size and size distribution
of the disrupted EAs. Large volume of blood-mimicking solution (400 mL) was required
for each analysis with the use of 2000 µm aperture. The number of particle analysis tests
was determined depending on the volume of solution collected during each experiment.
At least 5 runs were performed with the 400 µm aperture due to the small amount of
solution which was needed for each run. Average particle size (mean± standard error),
particle number, and size distribution were recorded.
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Results
Enterprise stent and MERCI Retriever were applied in 6 vessel occlusions each,
and with Penumbra aspiration and ultrasonic endovascular system, 5 procedures were
performed. A total of 22 experiments were conducted. Before occlusion, CCA and MCA
flow were 367.4±1.37ml/min and 130.40± 1.71 ml/min (mean± standard error),
respectively. Peak and minimal pressure of the MCA waveform were 116 and 81 mmHg,
respectively, mimicking the systolic and diastolic blood pressure.  The pressure gradient
between the inlet and outlet of the vascular replica was 21.96 mmHg. After occlusion,
MCA flow dropped to 0 ml/min, and an increase in pressure gradient between the
proximal and distal MCA was observed (Figure 4-3).
Figure 4-3 Variations of the hemodynamic variables before and after EA injection.
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The average diameter of the ICA siphon was 4.21 mm, and the ICA had a
maximum diameter of 5.7 mm (Figure 4-4 (a)). As a result of diameter differences
between the bovine EA and vascular replica, it was found the vascular occlusion was
formed at the MCA bifurcation (Figure 4-4 (b)). The nominal diameter of the MCA was
2.2 mm.
Figure 4-4 (a) The dimension and geometry of the ICA/MCA model (b) bovine EA with a diameter of
4.76 mm stopped before the MCA bifurcation.
Injection of EA and deployment of the device sometimes caused EA
fragmentation and distal dislocation. Figure 4-5 (a) showed that fragmented EAs were
seen in a test with the Enterprise stent. The stent was deployed distal to the EA, and
compressed the EA during EA retrieval (Figure 4-5 (a)-(c)). No significant amount of
visible EA particulates was generated due to the compression of the EA. Figure 4-5 (d)-(f)
illustrated that the EA slipped through the stent when passing the ICA siphon, and
resulted in an unsuccessful EA removal. This phenomenon was frequently observed in
other 5 Enterprise stent tests. It should be noted that temporary flow restoration (29.28%
±6.42%) was measured when the stent was self-expanded during the procedure. In 6
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experiments performed with the Enterprise stent, partial flow restoration (86.57%) was
achieved in 1 experiment when part of the EA was removed by the device (Figure 4-6).
The recanalization rate of the Enterprise stent in this study was 17%.
Figure 4-5 (a) to (c) Bovine EA was captured and compressed by the pulling maneuver. (d) to (f) The
stent-EA contact was lost during the EA retrival. Only the stent was withdrawn into the
guide catheter.
Figure 4-6 Bovine EA was successfully removed by the Enterprise stent.
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With the assistance of aspiration, MERCI L5 Retriever achieved a 67% of
recanalization rate (100% flow restoration was obtained). Like Enterprise stent, MERCI
L5 Retriever was navigated to the distal end of the EA (Figure 4-7 (a)); moreover, EA
was broken into few large pieces during the test (Figure 4-7 (b)). Successful EA
mobilization by the MERCI L5 Retriever was demonstrated in (Figure 4-7 (c)-(f)).
Bovine EA removed by the MERCI L5 Retriever was shown in Figure 4-8.
Figure 4-7 (a) and (b) MERCI L5 Retriever was deployed and ensnared the EA. (c) and (e) EA was
slowly travelled through the ICA and aspirated into the guild catheter, resulting in a
100% flow restoration (f).
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Figure 4-8 Bovine EA was removed by the MERCI L5 Retriever.
In the procedure with the use of Penumbra aspiration system, the reperfusion
catheter reached the proximal end of EA, and the separator moved back and forth to
disrupt the EA (Figure 4-9 (a)-(b)). The continuous aspiration-debulking process
provided by the Penumbra system produced some visible EA particulates (Figure 4-9 (b)).
After 2-3 passages of aspiration through the occluded area, 100% flow restoration was
seen in 1 test, partial flow restoration (Figure 4-9 (c)) was measured in 3 tests, and no
flow restoration was recorded in 1 test. Overall, the recanalization rate of Penumbra
aspiration system was 80%.
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Figure 4-9 Partial revascularization of the MCA using the Penumbra aspiration system. (a)The
reperfusion catheter was placed at the proximal end of the EA. (b) the separator
ruptured the EA, and generated particles with an average size of 238.8 µm.
No flow restoration and pressure change were seen in all ultrasound waveguide
treatments (Figure 4-10). The system was activated for 20 min in each occlusion. The
wire was in good shape after each test, without any evidence of wire fracture. To ensure
that the ultrasound waveguide system worked properly, the wire was embedded and
activated in the EA formed in the straight tube. The EA disruption was seen in 20
seconds after the device activation.
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Figure 4-10 No flow was restored after a 20-min treatment by using the ultrasound waveguide wire.
The weight of the EA residues showed that the MERCI retriever and Penumbra
aspiration device removed most of the EA (86% and 92%, respectively) as compared to
the Enterprise stent (58%) and ultrasound waveguide (54%). Thousands of small particles
with size smaller than 250 µm were analyzed in each device testing by using the 400µm
aperture, and a large proportion of particulates had size fell between 13.5 to 50 µm
(Figure 4-11(a)). Figure 4-11 (b) demonstrated that most large particles had size between
200 to 450 µm. By using the 2000µ aperture, it was found that the mean number and size
of the particles in the blank was 2.65±1.04 and 131.3±27.54 µm, respectively (Figure 4-
12 (a)). Figure 4-12 (b) showed that the Penumbra system generated more particles as
compared to the Enterprise stent, MERCI retriever and ultrasound-based device
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(MERCI:1.5±0.69; Penumbra:15.53±8.24; Enterprise:6.69±2.09; ultrasound:1.53±0.62).
In addition, large variations in quantity of large particles were seen with the use of the
Penumbra system. No significant difference in particle size was observed before and after
the experiments Figure 4-12 (c). The mean particle size was 169.4±37.94, 248.4±47.44,
200.3±34.02 and 101.9±29.29 for the MERCI retriever, Penumbra system, Enterprise
stent and ultrasound waveguide, respectively.
Figure 4-11 Size distribution of the particles generated by the thrombectomy devices.
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Figure 4-12 Number and size of the particles from the blank (a) and procedures conducted
with Enterprise stent, MERCI retriever, Penumbra aspiration device and ultrasound
waveguide (b-c). The measurements were performed with the use of the 2000 µm aperture.
Discussion
The in-vitro occlusion model system offers an alternative and convenient
approach for pre-clinical evaluation of mechanical thrombectomy devices, and has
advantages over the in-vivo animal model in terms of lower cost, high degree of
reproducibility, quantitative analysis and no ethical considerations. In this study, a
physiologically realistic model of cerebral occlusion was proposed and used to evaluate
the efficacy and safety of 4 mechanical thrombectomy devices.
Factors such as anatomy of the human carotid arteries, similarities between
embolus analogues and human sources of emboli, and hemodynamic variables were taken
into consideration in the development of the occlusion model. The transparent vascular
replica and the data acquisition system which incorporates the synchronized video
captured by a digital camcorder provide real time EA-device interaction. In the previous
work, to study the risk of emboli, the EA particulates were filtered by several meshes of
different size and weighed by a scale155, 195, 202. Instead of sieving, the dimension of the
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EA particulates was characterized by the Coulter principle. The disrupted EAs were
stored in the blood-mimicking solution (water/glycerol mixture) which was the perfect
solution for large apertures (400 and 2000µm) used in our application. During the
analysis, the EA particulates were drawn through the aperture, resulting in an impedance
change of the aperture. The change created a current fluctuation which was then
converted into a voltage pulse. The volume of the EA particulates was proportional to the
amplitude of the voltage pulse.
The Penumbra pivotal stroke trial completed in 2007 showed a racanalization
(TIMI 2 or 3) rate of 81.6% 100, which was similar to our finding (80%). In addition, the
observed recanalization rate of the MERCI L5 Retriever (67%), was also close to the
number disclosed in clinical studies (57.3%)98. The Enterprise stent tested in this study
had an unconstrained outer diameter of 4.5 mm which was smaller than the proximal
diameter of the ICA replica. Thus the EA became disengaged from the stent during the
retrieval process that explains the low recanalization rate of the Enterprise stent (17%).
Further, this observation demonstrates the need for proximal aspiration through a balloon
guidecatheter when using a stent system as a clot retriever. In a recent study, 90%
recanalization was attained in patients using a similar stent-retriever device, the Solitaire
system111. This device was deployed in AIS patients in whom the MERCI system failed
to restore blood flow. It is likely that the high success rate reported and not reproduced in
our model system may be attributed to two factors: 1. Our vascular replica had a focal
ectatic dilation in the cavernous segment that exceeds the unconstrained diameter of the
stent, and 2. Castaño et al. used a proximal temporary occlusion system (not approved
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with the Solitaire thrombectomy system) that combined with aspiration may be the
optimal adjunct technique for stent based thrombectomy technologies. EA fragmentation
caused by the ultrasound waveguide wire was seen in the occlusion formed in straight
tubing. However, no flow restoration was seen when activating this device in the
ICA/MCA occlusion model. The unsuccessful recanalization may be attributed to the
tortuosity of the cerebrovasculature which could impede the ultrasonic wave propagation.
To investigate the efficacy of the thrombectomy devices, the EA weight was
measured pre- and post-treatment. During the measurement, the EA weight was affected
by the amount of water/glycerol on the EA surface. To minimize the error, the excess
water/ glycerol was removed. Less remaining EA was found in the groups with higher
recanalization rate (the Penumbra and MERCI), which made it reasonable to suggest that
the more EA removed, the higher recanlization rate could be achieved.
The dimension of the largest particulates produced by the thrombectomy device
was between 700-950 µm, which was smaller than that of the particulates found in the
earlier in-vitro studies (>1000 µm)155, 195. This finding was due to the barium sulfate
effect on the mechanical properties of the EA. Barium sulfate reduced the elasticity and
increased the toughness of the EA. With the presence of barium sulfate, the EA was less
prone to break. More details regarding the mechanical properties of the EAs were stated
in the previous chapter. The results of the blank tests showed that thousands of particles
had dimension smaller than 100 µm, and the quantities varied in each blank test. Based
on this observation, it was postulated that the small particulates measured by the 400 µm
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aperture may include not only EA fragments but the small particles from the working
environment.
Conclusion
A physiologically realistic model system of MCA occlusion was created for
evaluation of the MERCI L5 Retriever, Penumbra aspiration system 054, self-expanding
Enterprise stent and ultrasound waveguide wire. The recanalization rate of the
thrombectomy device was related to the ability of the device to capture the EA during
removal of the device and the geometry of the cerebrovasculature. The risk of the
embolic shower was influenced by the mechanism of action for the thrombectomy device.
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Final Summary and Conclusions
Currently, there are no standardized or validated cerebrovascular occlusion model
systems with which to systematically evaluate and characterize mechanical
thrombectomy devices. Further, development of said model system could be extrapolated
to improve neurointerventional training of endovascular treatment in acute ischemic
stroke. This thesis rigorously addresses each component of a cerebrovascular occlusion
model system.
The 2D TOF MRA datasets were processed and edited to construct 3D vascular
models for vessel characterization in terms of AC, length and diameter. Based on the
results from the vessel characterization, a population averaged vasculature was
determined from 20 patients and used to create the core-shell mold for preparation of the
transparent and true-to-scale silicone replica. A simplified vascular replica consisting of
the ICA and MCA to the MCA bifurcation was used for vascular occlusion simulation.
Mechanical properties of various types of EAs commonly used in the lab were
explored and compared to those of the thromboemboli retrieved from AIS patients and
atherosclerotic plaques. In the preliminary tests of our model system, a radio-opaque
bovine EA with stiffness similar to the thrombi retrieved from the atherosclerotic plaques
was selected to form an occlusion in the aforesaid replica for thrombectomy device
testing. A computer-controlled pump was incorporated to generate a physiologically
realistic carotid waveform, and pumped blood-mimicking fluid through the replica.
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The MERCI L5 Retriever, Penumbra aspiration 054 system, Enterprise stent, and
ultrasound driven waveguide were evaluated by using the occlusion model system. The
flow restoration, the ability to achieve recanalization, size and size distribution of the EA
fragments were analyzed to assess the efficacy and safety of the testing devices. The
MERCI L5 Retriever and the Penumbra aspiration 054 system showed a 67 % and 80 %
recanalization rate, respectively, which were similar to the numbers reported in the
previous clinical studies, 57.3 % and 81.6 %, respectively. The Enterprise stent reliably
restored blood flow but was only successful at thrombectomy in one experiment. The
Penumbra system generated the most large clot fragments.
In conclusion, an anatomically and physiologically representative model system
of cerebrovascular occlusion was successfully built for evaluation of mechanical
thrombectomy devices in-vitro. Future work will include testing of thrombectomy
devices in more tortutous vascular replicas with various EA models. Our eventual goal is
to catalog a device performance envelop based on the mechanical properties of the
thromboemboli. Ultimately, advanced imaging algorithms may become available to
discern the composition of the embolus that when combined with the aforesaid catalog
could guide device selection. As more devices become available, this information would
be used to make the thrombectomy procedure more efficacious and cost-effective. The
research described herein provides the fundamental framework for attainment of this
challenging yet important goal.
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